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Abstract
In recent years much interest has focused on the early detection of breast 
carcinoma and the potential for prevention strategies for women at high risk, 
and this has been fuelled by the implementation of breast screening programmes 
which have increased the diagnosis of all forms of pre-invasive disease. The 
management of women found to have proliferative breast disease is 
unsatisfactory with mammographic surveillance being the only realistic option 
for these patients. It is therefore particularly important that the genetic profile of 
these lesions is comprehensively studied in order to detect potential biomarkers 
for progression and hence future avenues for therapeutic intervention and 
prevention.
The aim of the study is to reconstruct the molecular evolution of breast cancer 
progression with particular emphasis on the critical pre-invasive steps. It is 
hypothesised that a normal breast epithelium can evolve to breast cancer 
through the intermediary stages of proliferative disease without atypia [PDWA], 
atypical ductal hyperplasia [ADH] and ductal carcinoma in situ [DCIS].
The characterisation of genetic alterations shared by DCIS and invasive breast 
cancer has reinforced evidence that DCIS is a true non-obligate precursor of 
breast cancer, however there is little genetic evidence to substantiate the 
hypothesis that PDWA is a precursor of invasive breast cancer.
Our group had previously shown DCIS to have chromosomal imbalances 
involving chromosomes 1, 3, 10, 17 & 18, therefore 31 cases of PDWA were 
analysed by fluorescence in-situ hybridisation [FISH] using chromosome 
specific centromeric probes for chromosomes 1,3,10,17 &18.
Chromosomal imbalances affecting those chromosomes were detected in 
PDWA which mirror those found in DCIS but at a reduced frequency
suggesting that a subpopulation of PDWA resembles DCIS at a molecular level 
and are at a greater risk of progression.
A huge increase in the frequency of chromosomal imbalances affecting 
chromosomes 3 & 17 occurs between PDWA and DCIS thus key genetic events 
involved in the progression of PDWA to DCIS may be present on those 
chromosomes.
In contrast chromosome imbalances affecting chromosome 18 were present at a 
high frequency in both PDWA and DCIS suggesting that this chromosome 
harbours genes responsible for the earliest stages of breast cancer progression. 
There is therefore a requirement to define the regions of change in chromosome 
18 in more detail to identify candidate genes.
Multiple foci of DCIS from sections known to have a loss of chromosome 18 
sequences were therefore microdissected and three polymorphic microsatellite 
markers for chromosome 18 were PCR amplified in order to detect regional 
alterations to chromosome 18 and to investigate the phenomenon of intratumour 
genetic heterogeneity.
A high frequency of allelic imbalance was found for all the markers with the 
highest frequency incorporating the region of 18q23, suggesting that this region 
harbours genes crucial to the early progression of breast cancer.
Individual foci of DCIS exhibited a high degree of genetic heterogeneity for 
chromosome 18 which suggests that several subclones of DCIS may coexist 
within an individual.
These results set the agenda for the future investigation of genetic alterations in 
pre-invasive breast disease.
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Overview.
This thesis postulates a genetic basis for a hypothetical model of breast cancer 
progression whereby a normal breast epithelium can evolve through a number 
of morphological stages culminating in the invasive phenotype.
Recently developed techniques have been applied in order to identify and 
compare common genetic changes in benign and malignant tumours of the 
breast. The work has succeeded in showing that the same changes are present 
in the DNA of both types of lesions. This provides evidence for a common 
path, and also points to the early changes which may be responsible for the 
disease.
Chapter 1 examines why investigating the genetic basis of breast cancer is 
crucial and reviews the clinical evidence which is compatible with the 
hypothetical model of breast cancer progression. The chapter moves on to 
review the present knowledge of genetic alterations in both invasive breast 
cancer and pre-invasive disease.
Chapter 2 describes the molecular techniques employed to analyse pre- 
invasive breast disease by the author.
Chapter 3 marks the beginning of the results section and describes, with 
examples, how the experimental data was analysed and quantified.
Chapter 4 presents and discusses the results of the genetic analysis of 
proliferative breast disease without atypia [PDWA], which reveals genetic 
alterations similar to that of DCIS and invasive cancer.
Chapter 5 presents data and discussion on the involvement of the ERBB2 
oncogene in PDWA and DCIS.
x
Chapter 6 analyses and identifies regional changes on chromosome 18 in 
DCIS. Chromosome 18 was chosen for more detailed analysis due to the high 
frequency of genetic alterations found in both PDWA and DCIS which 
suggests that chromosome 18 harbours genes responsible for the earliest stages 
of breast cancer progression.
Chapter 7 provides a general summary of the thesis bringing together concepts 
from each of the chapters.
INTRODUCTION
Chapter 1.
Introduction.__________________________
1. Breast Cancer
1.1. Incidence and mortality
Breast cancer is the most common malignancy affecting women in Europe 
(180 000 cases per year) and the USA (130 000 cases per year). In European 
countries breast cancer constitutes 20% of all malignancies and represents a 
major public health problem (Willett et al. 1992). Steady progress continues to 
be made in the clinical management of breast cancer. However, advances in 
our understanding of the biology of breast cancer and pre-invasive breast 
cancer, particularly the genetic basis of inherited susceptibility to breast cancer 
are occurring at a more rapid pace. As these biologic processes are elucidated, 
intensive efforts are being made to translate this fundamental science into 
progress in the prevention, diagnosis and therapy of this common cancer.
Current estimates indicate that the cumulative lifetime risk of developing 
breast cancer is —10% and the lifetime risk of dying of breast cancer is 
—3.6%. Half of a woman’s risk occurs over the age of 65, with the majority of 
cancers occurring in women over 55. The risk for younger women, in the 
absence of other major risk factors other than age, is low and the chance of 
developing breast cancer between the ages of 35 and 55 is 2.5% (Hankey et al. 
1994; Gelb et al. 1985; Willett et al. 1992).
The incidence of breast cancer has been increasing in most Western countries 
since 1950 and continues to do so at a mean rate of 1 - 2% annually. The rate 
of increase is more pronounced in lower risk populations and thus the 
difference in incidence between women in low risk populations such as the Far 
East, and women living in the West will decrease (Willett et al. 1992). The 
most recent surge in breast cancer incidence rates in the 1980’s may well be 
attributable to the implementation of breast cancer screening programmes,
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however early mammographic detection cannot explain the underlying, long­
term annual increase in incidence of this disease,(Figure 1).
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Figure 1.: Age standardised incidence of breast cancer and mortality 
(The data are summerised from ICRF, Epidemiology Unit)
Although the incidence of breast cancer continues to increase, age - 
standardised mortality rates for breast cancer, world-wide, are tending to 
remain constant, (Figure 1) (Beral and Hermon, 1996). Several factors could 
be responsible for the decrease in mortality rates from breast cancer in the face 
of an increasing incidence: changes in death certification practises; changes in 
incidence rates due to changes in risk factors; increases in a more benign form 
of the disease; earlier detection; and improvements in treatment. Indications 
are that the earlier detection and possible improvements in treatment have 
improved survival to the extent that the increases in incidence are being offset 
(Willett et al. 1992). However, as the incidence of breast cancer increases it is 
crucial that multidisciplinary research into the aetiology of breast cancer 
continues, to decrease both the incidence and mortality of this disease.
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1.2. Therapy.
Currently therapy for primary operable breast cancer is based on the co­
operative expertise of a surgeon, oncologist and radiotherapist, who aim to 
manage the primary tumour, the axillary lymph nodes and prevent 
locoregional and distant recurrence by using adjuvant hormonal or 
chemotherapeutic agents.
The surgical management of breast cancer involves treatment of the primary 
tumour by either modified radical mastectomy or conservative breast surgery 
and either the sampling, clearing or monitoring of the ipsilateral axillary 
lymph nodes.
Many randomised trials have now established that in appropriately selected 
cases, a combination of wide local excision of the tumour together with 
radiotherapy is as effective as mastectomy, thus offering women a less 
mutilating and psychological scarring alternative (Early Breast Cancer 
Trialists' Collaborative Group, 1995; Friedman, A. et al. 1995). Many studies 
are now questioning whether radiotherapy is necessary for all tumours and in 
particular tumours less than 2cm.
The management of the axilla is more controversial. Preoperative clinical or 
radiological assessment of lymph node involvement is inaccurate and only 
pathological examination of excised nodes can provide accurate information. 
Those who support axillary clearance contend that it yields prognostic 
information on which oncologists can base decisions about adjuvant 
chemotherapy. However, others contend that decisions on adjuvant 
chemotherapy have already been made based on the pathological examination 
of the primary tumour and hence the 50% of women with breast cancer who 
have node negative disease would be spared the morbidity of an axillary 
procedure (Osteen and Harris, 1985; Feldman and Gardner, 1993; Heilman, 
1994). Current practise in Scotland is to clear the axilla. A possible answer to 
this dilemma is the ‘’sentinel node biopsy” ( the node most likely to drain the 
primary tumour) which can be found by a vital dye or radioactive tracer. The
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main studies of this confirm near perfect correlation with the nodal status of 
the dissected axilla. Thus, a simple local anaesthetic technique may well be 
able to predict the status of the axilla (Ku et al. 1996; Krag and Alex, 1996; 
Krasne et al. 1995).
However, despite advances in techniques, the surgical management of breast 
cancer has not made an impact on survival. Over half of women with operable 
breast cancer who undergo locoregional surgical management alone will die 
from metastatic disease and hence the only way to improve the chance of 
survival of these women is to use effective systemic treatment.
Randomised clinical trials have shown that chemotherapy, tamoxifen and 
ovarian ablation can reduce the frequency of relapses and prolong survival 
among patients with operable breast cancer and ipsilateral lymph-node 
metastases (Early Breast Cancer Trialists' Collaborative Group, 1992). As a 
result almost all patients receive adjuvant systemic therapy. Multiagent 
chemotherapy is the agent of choice for pre-menopausal women with node 
positive disease (Veronesi et al. 1977); for post-menopausal women, 
endocrine therapy, alone or in combination with chemotherapy is 
advantageous (Legault-Poisson et al. 1990; Ludwig Breast Cancer Study 
Group, 1984). If you summarise the effects of adjuvant therapy, the use of 
tamoxifen in women greater than 50 will reduce the annual odds of recurrence 
by 30% and the annual odds of death by 19% which.equates with 8 extra 
women alive at 10 years for every 100 women treated with stage I & II cancer. 
The use of adjuvant chemotherapy in women less than 50 reduces the annual 
odds of recurrence by 37% and the annual odds of death by 30%, which 
equates with an extra 14 women alive at 10 years for every 100 women treated 
with stage I & II cancer (Perren, 1995). Further follow up is required to 
determine whether these women are cured or that their ultimate death has just 
been delayed. Unfortunately, it is therefore apparent that cytotoxic and 
endocrine therapies have significant limitations and present survival estimates 
remain depressing, (Table 1).
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Survival of patients with breast cancer 
according to lymph node status
Survival of patients according to 
tumour stage
survival at 10 years stage survival at 5 years
All patients 45.9% I 84%'
Node -ve 64.9% II 71%
Node+ve 24.9% m 48%
1 -3  + nodes 37.5% IV 18%
>4 + nodes 13.4%
Table 1. Patient Survival According to Lymph Node Status and Stage 
of Breast Cancer. ( Data from *’ The ABC of Breast 
Disease/9 BMJ, Publications.)
In attempt to improve survival, intensive efforts have been made in the areas 
of genetic, clinical and population research to identify risk factors in women 
which can predict their susceptibility to breast cancer development in the hope 
that the natural history of developing breast cancers could be altered or 
prevented by early diagnosis and therapeutic intervention.
1.3. Risk factors for the development of breast cancer.
The aetiology of breast cancer appears to be multifactorial with a number of 
endogenous and exogenous factors known to increase the risk of breast cancer. 
Age, family history, benign breast disease and reproductive history are all 
endogenous factors which contribute to risk. Ionising radiation, diet, alcohol 
and pesticides are all exogenous factors which have been suggested to increase 
breast cancer risk, however other than the recognition of these factors, there is 
limited understanding of the scientific basis of the risk or the interactions 
between risk factors. The strength of a risk factor is indicated by its relative 
risk, however an elevated risk does not necessarily imply causation, but it does 
provide a framework for further research, (Figure 2).
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RISK RISK
CATEGORY
RELATIVE
RISK
Family History mother affected before 60 yrs 2 .0
mother affected after 60 yrs 1.4
two 1st degree relatives 4 - 6
Age at menarche 11 to 14yrs 1.5
15 yrs 1.3
Age o f child at 1 st birth 20 - 24 yrs 1.3
25 - 29 yrs 1.6
> 30 yrs 1.9
nulliparous 1.9
Age at menopause after 45yrs 1.5
before 45 yrs 0.7
oophorectom y <35 yrs 0 .4
Benign Breast D isease any benign disease 1.5
PDW A " 2.0
ADH 4.0
Radiation atomic aomb 3.0
repeat x-rays 1.5 - 2.0
Oral Contraceptive current use 1.5
past use 1.0
Hormone replacement current use all ages 1.4
ever use 1.0
past use 1.0
u se> 10yrs 1.5
Alcohol 1 drink/day 1.4
2 drinks/day 1.7
3 drinks/day 2 .0
i ~ i
Figure 2. Established and Probable Risk Factors for Breast Cancer. 
( Modified from NEJM, Vol 327, No.7)
1.31. Age
The incidence of breast cancer increases with age, slowing after the 
menopause.
1.32. Family history
Family history is the most widely recognised breast cancer risk factor. There 
appear to be two different levels of risk in women with a positive family 
history, (i) The first is due to a genetically inherited predisposition to breast 
cancer which accounts for only 4 - 5% of breast cancer cases, (ii) The second 
level of risk into which most women with a family history fall is associated 
with an increased familial incidence of breast cancer where familial clustering 
may be a result of shared genes, shared environmental exposures or both. The 
level of risk varies with the closeness of the affected relative and the age at 
which the relative developed breast cancer, (Figure 2). In contrast to the huge 
increase in risk group one affords, those women in group two have a risk of 
developing breast cancer which rarely exceeds 30% (Anderson, 1992; Howell 
et al. 1994).
At present, mutations in three genes, p53, BRCA-1 and BRCA-2 have been 
associated with a genetic predisposition to breast cancer, (group , one). The 
familial characteristics suggestive of a genetic predisposition to breast cancer 
are : multiple relatives with breast cancer; history of breast and ovarian cancer; 
early onset breast cancer; and bilateral breast cancer (Howell et al. 1994).
BRCA-1 . Mutations of the breast cancer predisposition gene BRCA-1, 
located on chromosome 17q21, are associated with a substantial risk of both 
breast and ovarian cancer. For women with these mutations, the estimated 
risk of developing breast cancer before the age of 50 is 50%, rising to 85% by 
the age of 65. The risk of a second breast cancer is 65% by the age of 70.
The risk of ovarian cancer is less well quantified and ranges from 20% to 
50%.
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In addition mutations of BRCA-1 are also associated with an increased risk of 
prostate cancer and colon cancer. Over 100 mutations of this gene have now 
been identified, but the risk attributable to each mutation is as yet unknown 
which also illustrates the complexity of breast cancer genetics (Collins, 1996).
BRCA-2 . Mutations of BRCA-2 located on chromosome 13ql2 -l3 carry the 
same level of risk for breast cancer as BRCA-1, however there is only a small 
increase in the risk of ovarian cancer. In addition BRCA-2 mutations are also 
associated with an increased risk of male breast cancer (Page et al. 1996).
p53. The Li Fraumeni syndrome, in which breast cancer occurs at an early age 
associated with soft tissue sarcoma, osteosarcoma, adrenal tumours, gliomas 
and other childhood tumours may be caused by mutations of the p53 tumour 
suppresser gene. Analysis has shown that approximately half of the families 
with this syndrome have a p53 mutation (Page et al. 1996).
1.33. Benign breast disease.
The strongest risk factors associated with the development of breast cancer 
have been shown to be a genetic predisposition and secondly the histological 
evidence of benign breast disease (Rosen, 1993). The term benign breast 
disease encompasses a group of pathological entities which have to be 
specifically defined as they have varying degrees of risk. Hence, benign breast 
lesions are now defined as being non-proliferative, proliferative and / or 
atypical (Dupont and Page, 1985).
Non-proliferative breast lesions are not associated with an increased risk of 
breast cancer, while proliferative breast disease is associated with a relative 
risk of (1.5 - 2.0) of subsequent breast cancer. Atypical hyperplasia ( ductal or 
lobular ) carries the greatest risk with a relative risk of (4 - 5). The interaction 
of risk factors is illustrated in those women who demonstrate both a family 
history and a diagnosis of atypical ductal hyperplasia. Their absolute risk of 
breast cancer increases to 20% at 15 years which equates with a relative risk of 
10, (Figure 3) (Page and Dupont, 1993; Palli et al. 1991; London et al. 1992;
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Dupont and Page, 1985; Page et al. 1984; Page and Dupont, 1990). 
Additionally, no further increase in the risk of breast cancer was demonstrated 
in those women who used exogenous oestrogen after their biopsy (Dupont et 
al. 1993).
Cumulative breast cancer incidence
45:
£ 40:
35 ;*3
-DU 30-©
£ 25
£ 20J
CQ
s 15*
£
s 10
U
5
0
Atypical hyperplasia — ► 
plus family history
J
Atypical hyperplasia
r- - - - - - -
j - ’j
Proliferative d isease 
N^without atypia
No proliferative disease
5 10 15 20 25
Years since benign biopsy
30 35
Figure 3. The absolute risk of subsequent breast cancer following 
a biopsy showing ADH. ( Modified from Page & Dupont 
New England Journal of Medicine, 1985.)
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1.34. Reproductive history and hormonal factors.
Breast cancer is certainly related to hormonal factors with many studies 
linking breast cancer incidence to the age of menarche, menopause and first 
pregnancy with the greatest risk associated with a long period of uninterrupted 
menstrual cycles. Some authors estimate a 20% reduction in breast cancer risk 
for each year that menarche is delayed (Lobo et al. 1987), however, others are 
more conservative in their estimates. Other factors that delay regular 
menstruation such as physical exercise may also decrease risk (Brown et al. 
1973). The age at menopause is also influential with women whose natural 
menopause occurs before 45 having half the relative risk of breast cancer than 
those women with a menopause after 55 (Cole et al. 1972).
Nulliparous women are at greater risk than those who are parous with a 
relative risk of about 1.4. The effect of term pregnancy on risk varies with 
age at first birth with some authors proposing that- women whose first 
pregnancy occurs after 30 have a 2 - 5 fold increase in risk compared to 
women whose first pregnancy is before 18 (Bzsuch et al. 1989). Again this 
risk varies between different investigators, (Figure 2). The effects of an 
incomplete pregnancy are as yet inconclusive (Bzsuch et al. 1989; Cole et al. 
1983).
The effect of the oral contraceptive pill and hormone replacement therapy 
have been and are being extensively studied, but no clear evidence on risk is 
obvious. Overall, their is no convincing evidence of an increased risk of breast 
cancer in women who have ever used oral contraceptives (Romieu et al 1990). 
Analyses of hormone replacement therapy have demonstrated more variable 
results, but two meta-analyses suggest small increases in risk associated with 
duration of usage (Rodigues-Canteras et al. 1992; Weiss et al. 1993).
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1.35. Dietary factors
The evidence for diet affecting breast cancer risk is limited, however the 
observation that national per capita fat consumption is correlated with breast 
cancer incidence and mortality suggests a possible link. Epidemiological 
studies have been inconclusive with a number of prospective trials failing to 
establish a correlation (Colditz et al. 1987).
Evidence does however exist which supports a relationship between a higher 
alcohol intake and breast cancer risk (Orza et al. 1988).
1.36. Environmental factors
Exposure to ionising radiation, either secondary to nuclear explosion or 
medical diagnostic and therapeutic procedures increases breast cancer risk, 
however, less than 1% of breast cancer is estimated to result from common 
diagnostic radiology (Sherman et al. 1989). Recently, a marked increase risk 
of breast cancer has been seen in women receiving irradiation for Hodgkin’s 
disease (Hoppe et al. 1993).
Other environmental influences such as exposure to electromagnetic fields, 
occupational exposures and organochlorine pesticides have been suggested as 
potential risks, but evidence is still lacking.
1.4. Breast screening programmes
Despite intensive research into various risk factors, the pathogenesis of breast 
cancer remains unresolved , with the prospect of primary prevention based on 
the identification and understanding of risk factors a distant reality.
However, one potentially important strategy in reducing mortality from breast 
cancer is earlier detection, based on the hypothesis that detecting the tumour 
before it has developed metastatic ability will prevent deaths. To date the only 
proven method of screening is mammography (Shapiro, 1989). Critics of 
screening suggested that simply by detecting tumours earlier will not
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necessarily decrease mortality. Screening may simply detect lethal cancers 
sooner (lead time bias), cancers that are growing slowly are less likely to be 
lethal (length time bias), or tumours with questionable malignant potential 
(overdiagnosis bias). In addition, women who opt to participate in screening 
programme may induce a selection bias.
Several randomised trials were set up in attempt to eliminate these criticisms 
and overall indicate that screening a population of women over 50 appears to 
decrease breast cancer mortality by approximately 25% (Anderson, J. et al. 
1990; U.K.Trial of Early Detection of Breast Cancer Group, 1988; Gad et al. 
1992; Janzon et al. 1988; Shapiro, 1989). Breast cancer screening was 
introduced in the U.K. in 1989.
As a result of screening, a new population of breast cancers are being seen 
with an increase in the diagnosis of small node negative invasive tumours, 
ductal carcinoma in-situ, tumours of a special type (with a better prognosis) 
and proliferative breast lesions (Dixon and Blarney, 1994).
Thus, we are now faced with the clinical dilemma of treating a population of 
tumours and potential pre-invasive lesions whose natural history and 
biological nature are undetermined. However, this explosion in the diagnosis 
of proliferative breast lesions and ductal carcinoma in-situ has fuelled 
intensive scientific interest in these lesions and their potential for subsequent 
progression to breast cancer.
1.5. Breast cancer progression.
This thesis postulates a genetic basis for a hypothetical model of breast cancer 
progression. This section reviews the clinical evidence which is compatible 
with such a model.
The present morphological model of breast cancer progression is based on 
Vogelstein’s observations that a normal colonic epithelium can evolve through
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a series of well defined genetic events, closely associated with morphological 
tumour progression to a colonic carcinoma (adenoma - carcinoma sequence ) 
(Fearon and Vogelstein 1990). This delineation of the genetic events involved 
in the evolution of colonic carcinoma has paved the way for the investigation 
of other solid tumours, such as melanoma (Hayward et al. 1995) and bladder 
cancer (Cordon-Cardo et al. 1993).
In the model proposed for breast cancer, a normal breast epithelium is 
hypothesised to evolve to invasive cancer via the pre-invasive stages of 
proliferative disease without atypia (PDWA), atypical ductal ductal 
hyperplasia (ADH) and ductal carcinoma in-situ (DCIS) (Allred et al. 1993; 
O'Connell et al. 1994). Each lesion within the model is envisioned as a non- 
obligate precursor of the next, in the sense that most* will pursue a stable 
natural history while others will accumulate a critical number of genetic 
alterations and progress to the next stage. While the majority of potential 
precursors never progress, they are morphologically similar to those that may 
have already undergone initiating or transforming genetic events, (Figure 4).
The genetic evidence for this hypothesis is limited and it is based primarily on 
epidemiological evidence and animal studies. For instance, the model is 
consistent with post-mortem studies which demonstrated that PDWA, ADH 
and DCIS are found progressively less frequently in the breasts of women 
dying from causes other than breast cancer (Bartow et al. 1987). Perhaps more 
compelling evidence is afforded by those studies which show an increased risk 
of later developing breast cancer after excision of either PDWA [Relative risk 
=(1.2 - 2)], ADH [Relative risk = (4 -6)] and DCIS [Relative risk = (10 - 12)] 
(Palli et al. 1991; London et al. 1992; Dupont and Page, 1985; Dupont et al. 
1993; Page et al. 1984; Page and Dupont, 1990). Additionally, lesions such as 
PDWA, ADH and DCIS are observed concurrently in over 50% of breasts 
containing invasive breast cancer (Bartow et al. 1987). Data from various 
sources suggest the risk for carcinoma is equally divided between both breasts 
following a diagnosis of PDWA or ADH (Alpers and Wellings, 1985). This 
bilateral risk is in striking contrast to the strong tendency for subsequent
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Figure 4. Morphological model of breast cancer evolution. Ductal breast 
cancer is hypothesised as evolving from a normal epithelium 
through a series of increasingly abnormal, but non-obligatory, 
cellular changes from hyperplasia to invasive carcinoma. 
(Modified from Allred et al 1993)
invasive carcinoma to arise in the ipsilateral breast following diagnosis of 
DCIS.
The hypothesis that breast cancers can evolve from precursor lesions in a 
stepwise fashion is further supported by experiments on mice in which breast 
epithelial cells in these animals undergo nodular proliferation to form 
hyperplastic alveolar nodules. When those lesions are transplanted into 
mammary fat pads they develop into tumours more frequently than normal 
breast tissue (Lakhani et al. 1996).
This model provides a framework for the investigation and identification of 
the morphological, cellular and molecular events involved in the progression 
to malignant breast disease. Adding to our present knowledge of pre-invasive 
breast disease by delineating specific genetic changes for each proposed stage 
of progression and their biological consequences should lead to a better 
understanding of the natural history of breast cancer and pre-invasive breast 
disease allowing the development of more rational means of treatment and 
prevention.
2. Pre-invasive breast disease.
2.1. Ductal carcinoma in-situ .
2.11. Epidemiology.
Until recently DCIS was regarded as a clinical oddity accounting for <5% of 
patients with symptomatic breast malignancies. DCIS frequently contains 
calcification and hence, with the widespread use of mammographic screening 
DCIS now compromises 15% - 30% of newly diagnosed carcinomas. This 
previous pathological oddity now imparts a significant impact on society, 
emphasising the importance of understanding its biology (Frykberg and Bland, 
1994).
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2.12. Pathology and natural history of DCIS.
The essential histologic feature of DCIS is ‘’confinement of malignant 
epithelial cells within their natural basement membrane boundaries” (Broders, 
1932). Previously DCIS was classified according to growth patterns within the 
duct system, (papillary, cribriform, solid and mixed) however this has proven 
to be unsatisfactory as there is much observer variation and DCIS specimens 
tend to have a mixture of patterns, (Figure 5 a). Consequently, the 
classification has little relationship to clinical outcome. Evidence is now 
emerging that DCIS is a heterogeneous entity both morphologically and 
biologically, hence there is a need to develop a reproducible morphological 
classification which can aid the clinician their planning of appropriate therapy.
Until recently most cases of DCIS were treated with mastectomy, however 
with the advent of conservative breast surgery this practise is being re­
evaluated. Follow up studies show that following a biopsy of DCIS (not 
complete excision), 14 -30% of women will subsequently develop invasive 
breast cancer, therefore mastectomy may be a radical overtreatment for many 
women (Frykberg and Bland, 1994). In trials with complete excision of DCIS 
there appears to be a recurrence rate of between 15% and 25% of which half 
are invasive, which is reduced with the addition of radiotherapy by 50% 
(Lagios and Page, 1993). Consequently, wide local excision with or without 
radiotherapy may well be an appropriate treatment for DCIS, therefore it is 
important to identify which types of DCIS are more likely to recur and which 
are amenable to excision alone. There are a number of new proposed 
classifications which combine pathological findings and clinical outcome, 
however the Van Nuys DCIS classification seems to be gaining preliminary 
acceptance as it divides DCIS into three easily distinguishable groups (non- 
high grade, without comedo necrosis; non-high grade, with comedo necrosis; 
and high grade ) each of which has a different likelihood of recurrence if 
treated with breast conservation therapy (Bellamy et al. 1993; Lennington et 
al. 1994; Holland et al. 1994; Silverstein et al. 1995). Randomised clinical 
trials, however, are still required to evaluate this • and other proposed 
classifications of DCIS.
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2.2. Proliferative breast disease.
There is a wide range in the degree of epithelial proliferation in benign breast 
disease and various attempts have been made to quantify both the degree of 
change and the magnitude of risk for breast cancer, however the studies of 
Dupont and Page have provided the gold standard, which has led to the 
American College of Pathologists recommending that patients with benign 
breast disease be grouped into Dupont and Page’s three categories of risk 
(Page and Dupont, 1993).
Risk associated with proliferative breast disease:
I No or mild hyperplasia: No risk
II Moderate or florid hyperplasia: 1 .5 -2  times the risk
III Atypical ductal hyperplasia 5 times the risk
2.21. Proliferative disease without atypia.
This area of breast pathology has been fraught with different terminology 
(papillomatosis, epitheliosis) leading to confusion, however most pathologists 
are now adopting the above classification where mild PDWA is made up of 3 
to 4 epithelial cells in thickness and moderate to florid PDWA when the 
appearances are more pronounced, (Figure 5c). A number of specific features 
identifying the benign nature of these lesions are also described. As yet there 
are no morphological indications of a particular subpopulation at a greater risk 
of progression.
2.22. Atypical ductal hyperplasia.
Post-mortem studies confirm that ADH has a prevalence of approximately 
2.5% - 4% in women in their forties (Bartow et al. 1987). ADH confers a 
relative risk = (5) for the development of breast carcinoma and a relative risk 
=(12) if associated with a positive family history (Dupont and Page, 1985). 
Further evidence to suggest the pre-cancerous nature of these lesions is the
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observation that invasive carcinoma and DCIS can arise in foci of ADH 
(Cardiff and Morris, 1987; Blair et al. 1959).
2.23. Pathology and Natural history
Atypical ductal hyperplasia is defined as ‘’hyperplasia of the ductal epithelium 
with some cytological and / or architectural criteria of DCIS, but is 
incompletely developed and not uniformly present throughout two complete 
duct spaces” (Figure 5b) (Page et al. 1984). The full histopathological criteria 
for the recognition of ADH are well recognised, however pathologists still 
fail to concur frequently, which is well illustrated in a recent study where six 
experienced breast pathologists examined cases of PDWA, ADH and DCIS. 
Strict criteria were laid down for diagnosing ADH, but the pathologists agreed 
in only 58% of cases (Gelman, R. et al) . Given the similarity of ADH to low 
grade non-comedo DCIS there is a school of thought that ADH represents the 
lower end of a continuum of DCIS. A grey area therefore exists at that end of 
the spectrum of DCIS. This may account for the low incidence of reported 
ADH because a diagnosis of DCIS is the ‘safer option’ as these women will 
undergo formal treatment, whereas women with ADH will merely undergo 
clinical and mammographic follow-up.
3. Somatic genetic alterations in breast cancer.
3.1. Introduction.
Invasive breast cancer has been the subject of intensive molecular genetic 
investigation in recent years with the intention of identifying common genetic 
alterations which will enhance the present understanding of breast 
carcinogenesis and hopefully lead to the development of improved therapies 
and novel treatments.
The contemporary view of carcinogenesis, whereby a tumour arises from 
cellular transformation, loss of contact inhibition and acquisition of invasive 
capacity as a result of successive mutations, is in keeping with the present 
model of breast cancer progression (Fearon and Vogelstein, 1989; Nowell, 
1976; Fearon and Vogelstein, 1990; Devilee et al. 1994a). According to this
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hypothesis, a cell that acquires specific genetic alterations may develop a 
proliferative advantage and the clonal expansion of this cell driven by 
successive mutations, can lead to tumour progression. A substantial amount of 
evidence is available which indicates that the process of carcinogenesis 
requires this sequential accumulation of a number of genetic alterations. These 
genetic alterations are thought to be effected through activating and 
inactivating mechanisms involving two classes of gene (protooncogenes and 
tumour suppresser genes) (Bieche, and Lidereau, 1995; Fearon and 
Vogelstein, 1990).
An elegant example of how these type of genes may interact to cause 
disregulated cell growth and tumour promotion is the recent model of tumour - 
promoting events within the G1 control pathway (Figure 6). This has resulted 
from the recent discoveries in the fields of cell-cycle regulation and 
tumourigenesis merging to reveal the molecular basis of the ‘’R” point or 
‘’restriction point.” This is a kind of molecular switch, within the cell-cycle, 
between the alternate routes of cell division, temporary cell-cycle arrest, 
quiescence, differentiation and cell death. If defective, loss of restriction point 
control has been found to be associated with malignant transformation (Bartek 
et al. 1995).
Recent discoveries have confirmed earlier predictions that R-point regulation 
can be ascribed to proteins encoded by known genes. Implicated are the D- 
type cyclins (cyclin Dl), the retinoblastoma protein (pRB) as the major 
negative regulator and the cyclin-dependent kinases and their inhibitors (p i6). 
Thus amplification of the protooncogene cyclin Dl or loss of the tumour 
suppresser genes p i6 and pRB can independently or co-operatively 
disregulate the equilibrium of cell cycle control and facilitate progression into 
the S-phase and possible malignant transformation. (Bartek et al. 1995).
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Figure 6. Model of tumour producing events within the G1
control pathway; Progression into S-phase is facilitated by 
either loss of p l6  [ A ]. or overexpression of cyclin D l f B ], or 
loss of the pRB target normally restraining premature S-phase 
entry[ D]. (Modified from Bartek et al 1995)
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Somatic genetic alterations have been studied in breast cancer using a number 
of techniques: Flow cytometry; cytogenetics, in-situ hybridisation and 
molecular analysis.
3.2. Flow cytometry.
Breast cancer has been extensively studied by flow cytometry demonstrating 
that 60% -80% of invasive carcinomas are aneuploid and that 10% - 15% 
contain multiple aneuploid stemlines, providing evidence of tumour 
heterogeneity. Disappointingly, ploidy has subsequently been found to be of 
little prognostic value (Devilee and Comelisse, 1990).
3.3. Cytogenetic analysis.
Prior to the advent of advanced cytogenetic and molecular techniques, 
classical cytogenetic analysis involved the karyotyping of breast tumours. 
These studies revealed that numerical changes affecting whole chromosomes 
were the most prevalent change, involving all chromosomes. ( Trisomy of 
chromosomes 7 and 18 and monosomies of chromosomes 6,8,11,13,16,17,22 
& X). A small number of studies have also identified a single clonal 
abnormality which may have been crucial to tumourigenesis, [ i(lq) & 
del(3)(p 12-p 14)] (Heim et al. 1995; Zafrani and Dutrillaux, 1990). Due to the 
technical difficulties of karyotyping solid tumours relatively few breast 
tumours have been analysed in this way, however the abnormalities are 
consistent with those found and further refined by molecular techniques.
3.4. In-situ hybridisation.
Fluorescence in-situ hybridisation (FISH) and comparative genomic 
hybridisation (CGH) are new developments in cytogenetic analysis which 
increases its resolution and avoids the need for in-vitro cell culture.
CGH has the ability to detect, in particular, regions of amplification in a 
genome. The technique involves in-situ hybridisation of DNA from normal
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and tumour DNA to metaphase chromosomes. Each DNA is labelled with a 
different modified nucleotide which is revealed separately by specific 
antibodies labelled with fluorochromes. Increases or decreases in 
fluorochrome ratios along the chromosome indicate regions of increased or 
decreased copy number in the tumour. CGH in combination with chromosome 
microdissection has revealed some 20 amplified regions in breast cancers 
(Waldman and Kallioniemi, 1994; Trent et al. 1994; Muleris et al. 1995, 
James et al. 1997).
The most frequently amplified regions are shown in (Table 5). Many whole 
arm changes have been reported before, however most of the regional copy- 
number changes have not. 17q22-24 and 20ql3 have emerged as major 
regions of amplification by several authors, suggesting that these loci may 
harbour previously unknown genes important in breast cancer progression 
(Waldman and Kallioniemi, 1994; James et al 1997).
FISH detects, locates and quantifies specific nucleotide sequences (DNA or 
RNA) in tissue sections, cells or chromosomal preparations. It has been used 
to study several genes (ERBB2, RBI) and is also useful for studying 
chromosomal mechanisms leading to loss of heterozygosity (LOH) as detected 
by molecular techniques.
3.5. Molecular analysis.
The advent of recombinant DNA technology has revealed that DNA 
amplification (mainly protooncogenes encoding growth factors and their 
receptors ) and mutations and LOH that could inactivate tumour suppresser 
genes are the most frequently observed genetic anomalies in breast cancer.
3.51. Loss of heterozygosity / allelic imbalance
The first tumour suppresser gene to be isolated was the gene for 
retinoblastoma (RBI) and is thought to contribute to carcinogenesis by its 
functional inactivation of both the alleles of the gene. This has also been 
demonstrated in other genes. In familial tumours, the first inactivating
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mutation is recessive and thus can be passed through the germline. The second 
mutation occurs at the somatic level resulting in the absence of the gene 
product. In non-familial tumours the ‘’two hits”  both occur at the somatic 
level. (Knudson, 1993).
In the case of RBI the second mutation leads to loss of the wild type allele 
which can be demonstrated via molecular techniques which exploit natural 
polymorphisms in human DNA which distinguish the parental and maternal 
alleles. Thus in a tumour heterozygous for a certain polymorphism the loss of 
one of the alleles can be demonstrated. The tumour is now said to display loss 
of heterozygosity (LOH) as it is hemizygous for the mutated allele. These 
mechanisms proposed for RBI have been verified in other tumour suppresser 
genes.
Hence, the finding of frequent LOH at a particular chromosomal locus 
highlights the presence of a tumour suppresser gene or genes at that locus. In 
practise polymorphic DNA markers will reveal gain and loss of an allele 
therefore it can be difficult to interpret allelic signals, hence the adoption of 
the term allelic imbalance to describe this concept.
A vast number of publications have demonstrated that chromosome 
involvement in breast cancer is complex with 16 chromosome arms showing 
an average LOH frequency of over 20% (Barnes et al. 1990; Smith et al. 1989; 
Saunders et al. 1989; Evans et al. 1988; Smith et al. 1992; Nakamori et al. 
1990; Callahan et al. 1990; Wiseman et al. 1992; Nakamura et al. 1994; 
Devilee et al. 1994; Callahan et al. 1987; Callahan et al. 1989; Carter et al. 
1993; Sellberg et al. 1992; Nakamori et al. 1919; Lidereau and Bieche, I, 
1993; Wenngren et al. 1992; Liscia et al. 1992; Comelisse et al. 1991a; 
Comelisse et al. 1991b; Comelisse and Devilee, 1990; Fearon and Vogelstein, 
1989). Despite this huge amount of data uncertainty still exists on how to 
interpret this data, however there is cytogenetic and molecular concurrence on 
the involvement of chromosomes 1, 3, lip , 16q, 17p, 17q, 18q and 22q in
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breast cancer progression. Table 2, summarises LOH data from a number of 
those studies of invasive breast cancer.
Most of the altered regions are also subject to LOH in other solid tumours 
which implies that in those regions, a single suppresser gene may be 
implicated in the progression of different tumours, perhaps at different stages 
or alternatively there may be several genes in each region, each of which have 
a role in one type of cancer.
Certainly a number of deleted regions in breast cancer involve known tumour 
suppresser loci, (Table 3). (Bieche, and Lidereau, 1995) Hence, there are a 
number of candidate genes which could be involved in breast carcinogenesis, 
(Table 6). It should be emphasised that many of the deleted regions observed 
in breast cancer will not lead to the discovery of tumour suppresser genes as 
certain deletions may deregulate the expression of neighbouring genes by a 
gene dosage effect.
3.52. Gene amplification.
Amplification of a gene is the result of overreplication that confers a growth 
advantage through increased levels of the protein encoded by the amplified 
gene. Usually a genomic region of considerable size is co-ampified, thus 
making it difficult to determine which of the genes in an amplified region 
provides a growth advantage. To date several amplified genes and regions 
have been detected in breast cancer, (Table 4 and Table 5), (Waldman and 
Kallioniemi, 1994; Trent et al. 1994; Muleris et al. 1995, James et al. 1997, 
Bieche, and Lidereau, 1995). Three regions harbouring protooncogenes that 
encode growth factors or their receptors are the most commonly amplified 
regions in breast cancer: ERBB2, MYC and llq l3 , (Table 4). Gene 
amplifications are usually correlated with a high level of mRNA and protein 
but not universally as overexpression without amplification may occur due 
alterations of the regulatory sequences of the gene.
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Chromosome
arms
Average 
LOH (%)
Range
(%)
No. of 
studies
lp 23 3 - 5 2 12
iq 32 1 2 - 3 4 9
3p 19 1 0 - 4 7 5
6q 20 7 - 4 8 9
7q 22 0 - 4 0 3
8p 24 1 8- 33 3
9q 25 9 - 3 6 12
l i p 16 10-41 . 9
l l q 27 0 - 4 3 12
13q 21 1 5 - 4 5 3
14q 23 1 3 - 2 8 3
15q 29 1 5 - 3 7 7
16q 49 2 8 - 6 3 21
17p 39 3 4 - 7 5 17
17q 49 2 2 - 7 9 8
18q 23 3 - 3 4 6
22q 26 0 - 3 8 14
Table 2. Loss of heterozygosity in breast cancer.
Gene Malignancy Locus
BRCA-1 Breast & ovarian 17q21
BRCA-2 Breast 13ql2 - 13
p53 Breast (Li Fraumeni) 17pl3.1
MSH2 Colon (HNPCC) 2pl5 - 16
MLH1 Colon (NNPCC) 3p
APC Colon (polyposis coli) 5q21
MCC Colon 5q21
DCC Colon 18q21
RET Thyroid (MEN 2A/B) lO q ll-12
WTI Wilms’ tumour l lp l3
RBI Retinoblastoma 13ql4
NF1 Neurofibromatosis I 17qll.2
NF2 Neurofibromatosis II 22ql2
VHL Von Hippel-Lindau 3p25 - 26
Table 3. Genes associated with tumour suppression 
or increased cancer susceptability
Gene Locus %
FGFR1 lq21 6
EGFR 7pl2-13 3
MYC 8q24 6-23
FGFR2 10q26 6
FGF3 1 lql3 4-23
IGF1R 15q25 2
ERBB2 17ql2 15-30
Ampified loci by 'CGH
lq21
8q22-24
9pl3
llp l3
16pll
17q21.1
20ql2-13.2
Table 4. Genes Known to be Amplified 
in Breast Cancer and Frequency of 
amplification
Table 5. Loci Found to be 
amplified in Breast Cancer 
by CGH
ERBB2.
The ERBB2 protooncogene belongs to the ERBB family (ERBB1, ERBB2, 
ERBB3 & ERBB4) which encode transmembrane receptors with tyrosine 
kinase activity. ERBB1 encodes the epidermal growth factor receptor (EGF). 
ERBB2 encodes for a 185-kDa transmembrane receptor whose extracellular 
region is very similar to that of the epidermal growth factor receptor (Bieche, 
and Lidereau, 1995). ERBB2 is the most extensively studied gene in breast 
cancer and is amplified and overexpressed in 15% - 25% of invasive breast 
cancers and with variable frequency in other solid tumours, (Table 4) (Bieche, 
and Lidereau, 1995; Chen et al. 1995; Allred et al. 1992). Association of 
ERBB2 amplification and overexpression with rapid proliferation, low 
oestrogen receptor content and high grade DCIS suggest that this oncogene 
plays an important role in breast cancer progression (Allred et al. 1992).
In addition to genetic studies ERBB2 has and is being extensively investigated 
in clinical trials as a molecular marker of potential prognostic significance in 
breast cancer. In the U.K. about 50% of breast cancer sufferers present without 
axillary node involvement and appear to be cured, but unfortunately some 
25% to 30% of these women will die of disseminated disease. At the moment 
there is no molecular markers which can help to prospectively identify women
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Locus Candidate
genes
lp l3  - 21 ----- ► RAP1A
lp32 - pter ----- ► RAP1GA1
3p21 -23 THRB
----- ►
RARB
PTPG
6q24 - 27 
1 lp l  5.5 —
----- ►
----- ►
----- ►
ESR
IGF2
H19
1 lq23 ----- ► Cyclin D l
13ql2 - 13 ----- ► BRCA-2
13ql4.1 ----- ► RBI
16q22.1 ----- ► CDH1
17pl3.1 ----- ► p53
17ql2 - 21 h----- ►
-----►
NME1
BRCA-1
NF1
PHB
MDC
18q21.3 -23 ------► DCC
------ ►
PLANH2
Maspin
DPC4
22ql2 ------ ► NF2
Table 6. Candidate Genes Involved in Breast Cancer
at greater risk of recurrence who would benefit from systemic treatment. Most 
node negative pre-menopausal women receive chemotherapy, which results in 
70% of women suffering the morbidity of chemotherapy unnecessarily. 
Studies to date have shown ERBB2 amplification and/or overexpression to be 
associated with a poor prognosis only in node positive disease with results 
from node negative disease remaining inconclusive (Miller,WR. 1994).
MYC.
Myc is a member of a family of genes including MYCL1 and MYCN, 
however only MYC is amplified in breast cancer. The frequency of reported 
amplification varies from 4% to 41%. The MYC protooncogene encodes for a 
59 - 62 kDa nuclear protein involved in the control of normal growth, 
differentiation and apoptosis. It has been proposed to play an important role in 
embryogenesis, cell growth and the tissue repair process. Overexpression is 
reported without amplification, therefore MYC may be activated by means 
other than gene amplification. Clinical trials have failed to show MYC of any 
prognostic significance to date (Riou et al. 1988).
Amplification of llq l3 .
The l lq l3  band is amplified in 15% - 20% of invasive breast cancers (Escot 
et al. 1988). Results demonstrate that there are at least four independently 
amplified regions and different genetic rearrangements. The amplicon contains 
a number of genes potentially involved in breast tumourigenesis: FGF3, FGF4, 
GSTP1, EMS1 & CCND1 (Bieche, I and Lidereau, 1995).
FGF3 and FGF4 are frequently co-amplified in breast cancer and due to their 
involvement in mouse tumourigenesis were thought to be good candidate 
genes for a role in human cancer, however their expression is undetectable 
which implies that the amplicon contains a gene responsible for a selective 
advantage (Bieche, and Lidereau, 1995).
GSTP1, EMS1 and CCND1 amplification is associated with overexpression of 
their products. GSTP1 is amplified in 5% - 10% of breast cancers and has 
been muted as a gene responsible for amplicon selection due to its proximal
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site on the amplicon. CCND1 encodes a protein of the cyclin family, coding 
for cyclin Dl. Cyclin Dl seems to regulate the G1 - S restriction point in 
association with CDK4 kinase. The role of the cyclins in breast cancer 
progression remains to be seen, although overexpression of cyclin Dl is 
common in breast cancer (Weinstat-Saslow, D., et al 1995).
3.6. Tumour heterogeneity.
Flow cytometry has demonstrated breast carcinomas with multiple, aneuploid 
clones which provides good evidence of intratumour genetic heterogeneity. In 
studies the degree of heterogeneity found is proportional to the number of 
areas sampled with up to 60% of tumours showing greater than one aneuploid 
cell line (Comelisse and Devilee. 1990). This hypothesis of intratumour 
heterogeneity is supported by karyotypic and in-situ hybridisation studies 
(Fearon and Vogelstein, 1990).
Ductal carcinoma in-situ constitutes a diverse and complex group of lesions 
with extensive intertumour heterogeneity. Recent molecular analyses, where 
multiple tumour foci were analysed for LOH, have suggested that DCIS may 
also exhibit extensive intratumour heterogeneity (Tsuda et al. 1995). This 
observation suggests the existence of multiple genetically diverse subclones 
within a section of DCIS and has implications for the future analysis and 
interpretation of LOH studies. For instance if only one tumour focus is 
investigated the frequency of genetic alterations may be underestimated or 
missed. More importantly, if multiple subclones of DCIS exist, there is the 
potential to detect genetic alterations in different clones and perhaps identify 
alterations that are associated with transformation to the malignant phenotype.
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4. Somatic Genetic Alterations in Pre-invasive Breast 
Disease.
The role of chromosome abnormalities in invasive breast cancer has been 
extensively studied. However, due to the complexity of the alterations no clear 
genetic model of the critical events involved in breast cancer progression has 
emerged. However, the methodology employed and the data obtained from 
invasive cancer has set the agenda for the investigation of pre-invasive breast 
disease. During the process of clonal evolution and malignant transformation, 
critical genetic changes could occur at an early stage, hence it is important to 
understand the emerging order of genetic alterations in breast cancer 
progression and their relation to histopathological stage.
By gaining a better understanding of the molecular characteristics of pre- 
invasive breast disease, the critical issue of the likelihood that PDWA, ADH 
and most importantly DCIS will progress to breast cancer may be answered 
and the model of breast cancer progression strengthened.
4.1. Genetic alterations in ductal carcinoma in-situ.
The characterisation of genetic alterations shared by DCIS and invasive breast 
cancer has reinforced evidence that DCIS is a true precursor of breast cancer, 
however, relatively little is known about early genetic changes associated with 
the transformation of normal breast epithelium to the malignant phenotype.
Progress in defining the molecular characteristics of DCIS indicates that DCIS 
is a non - obligate precursor of invasive breast cancer, but markers for 
identifying DCIS with a high potential for invasion have not yet been found. 
Evidence for this is primarily based on LOH studies of DCIS and comparative 
LOH and CGH studies of DCIS and invasive carcinoma from the same 
specimen (Waldman and Kallioniemi, 1994; Trent et al. 1994; Fearon and 
Vogelstein, 1990; Muleris et al. 1995; James et al. 1997).
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The allelotyping of DCIS has demonstrated a high frequency of allelic 
imbalance on chromosomes lp,lq,6q,8p,llq,13q,16q,17p,17q and 18q which 
mirrors alterations found in invasive cancer, (Table 7), (James et al 1997; 
Stratton et al. 1995; Aldaz et al. 1995; Murphy et al. 1995; Fujii et al. 1996; 
Allred et al. 1993; Harrison et al. 1995; Radford et al. 1995). The relation of 
LOH% to grade of DCIS suggests that alterations affecting 16q and 17p occur 
at a high frequency in low grade DCIS suggesting that those chromosomes 
may be involved in an early stage of progression. When invasive disease co­
existed the majority of allelic imbalances were present in both in-situ and 
invasive components.
Preliminary studies using comparative genomic hybridisaton reveal that 
chromosome alterations in pure DCIS and DCIS in the presence of invasive 
cancer, are of a similar pattern. Gains involving lq, 8q, and 17q were frequent 
as were losses of 8p, 16q and 17p. Paired samples of DCIS and invasive 
cancer from the same patients showed almost identical changes, suggestive of 
close clonal relationships (Waldman and Kallioniemi, 1994; Trent et al. 1994; 
Muleris et al. 1995).
The amplification of the ERBB2 oncogene in DCIS has been reported as high 
as 66% (Liu et al. 1992; Hubbard et al. 1994; Allred et al. 1992), however, 
those analyses relied on differential PCR techniques and, in the absence of 
control loci from chromosome 17, polysomy of chromosome 17 may be 
misinterpreted as ERBB2 amplification. It is therefore possible that those 
studies overestimated the true ERBB2 gene frequency in DCIS because of the 
high frequency of polysomy of chromosome 17. Indeed, subsequent studies 
using FISH which are controlled for chromosome 17 polysomy, demonstrate 
frequency of amplification in keeping with that of invasive cancer (Murphy et 
al. 1995).
Preliminary analysis also reveals the overexpression of BRCA-1 in DCIS 
which may indicate a role as a tumour suppresser during the evolution of 
DCIS to invasive disease (Munn et al. 1996).
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Locus DCIS - LOH frequency (%)
lp 30
lq 28
2p-ter
6q 32
8p 18,7
9p 30
l ip 44
iiq 33
13q 39 18 -
16q 51 29 28.6 25 33
1?P 68 41 37.5 29
17q 60 11 15.9 29 22
18q 16 10.7
Authors Fujji Tsuda Radford Aldaz O’Connell
Table 7. Loss of Heterozygosity in Ductal Carcinoma i n - s i t u  
(Summary of the most Recent Data)
4.2. Genetic alterations in proliferative breast disease.
Substantial evidence exists to support the view that a fundamental feature of 
breast cancer evolution is the accumulation of multiple genetic alterations, 
however evidence of such alterations in ADH and PDWA is sparse and 
inconclusive. For instance flow cytometry has demonstrated aeuploidy in 
approximately 36% of atypical ductal hyperplasia. (Micale et al. 1994). LOH 
analysis of PDWA and ADH has been very limited with a small number of 
studies showing low frequencies of allelic imbalance on 16q and 17p, 
although a wide array of markers were not used (Lakhani et al. 1995). Levels 
of Expression of Cylcin D1 have been found to be markedly lower in ADH 
than DCIS, which was interpreted to differentiate between low grade DCIS 
and ADH (Weinstat-Saslow et al. 1995). Other than this a comprehensive 
genetic analysis of proliferative disease is not yet available.
5. Identification of Genetic Alterations in Pre-invasive 
Breast Disease.
In recent years much interest has focused on the early detection of breast 
carcinoma and the potential for prevention strategies for women at high risk, 
and this has been fuelled by the implementation of breast screening 
programmes which have increased the diagnosis of all forms of pre-invasive 
disease. The management of women found to have proliferative breast disease 
is unsatisfactory with mammographic surveillance being the only realistic 
option for these patients. It is therefore particularly important that the genetic 
profile of these lesions is comprehensively studied in order to detect potential 
biomarkers for progression and hence future avenues for therapeutic 
intervention and prevention.
Traditional molecular and cytogenetic analyses have been hampered by the 
small and heterogeneous nature of DCIS and proliferative lesions. Our group 
and other investigators have used cytogenetic techniques to study
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chromosomal alterations in DCIS, as interphase cytogenetics allows the 
histological distribution of genetic alterations to be identified. Our group have 
previously found DCIS to have extensive chromosomal imbalances affecting 
chromosomes 1, 3, 10, 17, and 18 (Murphy et al. 1995). The aim of the study 
was to firstly establish a genetic link between PDWA and DCIS using FISH 
and thereafter use the more sophisticated recombinant DNA technology to 
pusue in more detail the genetic alterations which could link PDWA and 
DCIS.
6. Aims
The purpose of the following study was two-fold : -
(i) To analyse sections of isolated PDWA using interphase cytogenetics 
(fluorescence in-situ hybridisation) to identify gene alterations and 
chromosomal imbalances in PDWA, the earliest proposed 
morphological stage of breast cancer progression.
(ii) To analyse multiple, microdissected tumour foci from sections of 
DCIS, previously found to demonstrate a loss of chromosome 18 
sequences by FISH, in order to investigate the phenomenon of intra 
tumour heterogeneity and identify regional alterations on 
chromosome 18
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MATERIALS
and
METHODS
Chapter 2
Materials and Methods
2.1. Materials.
2.11. Chemicals.
All chemicals were obtained from the following manufacturers unless 
otherwise stated: BDH Chemicals Ltd., GIBCO BRL, and Pharmacia LKB 
Biotechnology.
Alpha Laboratories, Eastleigh, Hants.
Streck Tissue Fixative
Amersham International PLC. Amersham. Bucks.
<x32P dCTP
Beatson Institute Central Services 
PBS
Boehringer Mannheim UK Ltd., Lewes, East Sussex. 
proteinase K 
. DAPI 
Taq polymerase 
PCR buffer / Mg2+
Block
National Diagnostics, Atlanta Georgia 
Sequagel Sequencing System 
Sequagel Concentrate 
Sequagel Diluent & Buffer
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Promega Ltd.. Milton Keynes, Bucks.
dNTPs
Taq polymerase
Research Genetics, Huntsville, AL. 
Human MapPairs™
Sigma Chemical Co.. Ltd.. Poole.Dorset
Tween 20
TEMED
bromophenol blue 
xylene cyanol 
proteinase K 
Pepsin
Propidium iodide
Vector Laboratories Inc.. Burlington. USA 
Vectashield antifade mounting medium.
2.12. General Solutions.
20 x SSC
3 M NaCl
0.3M Tri-sodium citrate
TBE (xl)
89mM Tris Borate 
89mM Boric Acid 
2.5mM EDTA
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TAE (xl)
40mM Tris base 
20mM EDTA 
20mM NaCl 
20mM Na Acetate
PBS
20 PBS (Dulbecco ‘A’) formulated tablets (OXOID, Unipath LTD.) 
PER 2 Litres of distilled water
2.13. Gel running Solutions.
8% Polyacrylamide Gel
15mL Sequagel Concentrate 
39mL Sequagel Diluent 
6mL Sequagel Buffer 
150 pL APS 
75pL TEMED
DNA Loading Dye
0.25% bromophenol blue 
0.25% xylene cyanol FF 
30% glycerol
2.14. FISH solutions.
70% Hybridisation Solution for Centromeric Probes
70% formamide 
2 x SSC
5% Dextran sulphate 
500ug/mL salmon sperm DNA
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50% Hybridisation Solution for Single-Copy Probes
50% formamide 
2 x SSC
10% Dextran sulphate 
500ug/mL salmon sperm DNA
Denaturation Solution
70% formamide in 2 x SSC at 70 - 80°C
10% Block Solution Stock
10% Boehringer Mannheim blocking reagent in maleic buffer. 
Microwave until solution becomes turbid and autoclave.
Used at a concentration of 0.5% in maleic acid buffer/Tween 
4 x SSC-T or PN-T buffer
4 x SSC Wash Solution
4 x SSC
0.05% Tween 20 
PN buffer
Mix of 0.1M NaH2P04 and Na2HP04
PN-T
PN buffer 
0.05% Tween
2.15. Antibodies.
Boehringer Mannheim UK Ltd.. Lewes. East Sussex 
anti-digoxigenin ( affinity purified sheep IgG)
Stratech. Luton. Bedfordshire
Fluorescein ( FITC ) conjugated AffinitiPure Donkey Anti-Sheep IgG
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2.16. FISH probes.
Appligene Oncor. Durham 
Chromosome-specific repetitive sequence probes
Vvsis Inc.. Downers Grove. II
Locus Specific Identifier probe (LSI®) Her 2/neu Spectrum Orange™ : CEP® 
17 Spectrum Green
2.17. Equipment and Plasticware
Eastmann Kodak Co., Rochester, New York 
X - ray film
Fuiii Photo Co., Ltd., Japan 
X - ray film
Gibco Europe, Life Technologies Ltd., Paisley 
Gel running apparatus
Greiner Laboratechnik Ltd., Durslev 
Eppindorfs
aerosol resistant pipette tips
Hvbaid Ltd., Teddington, Middlesex 
Omnislide in-situ system 
PCR thermal cycler
Whatman International Ltd.. Maidstone 
3MMM paper
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2.2. Fluorescence In-Situ Hybridisation.
2.21. Study Population.
A group of 37 formalin-fixed, paraffin embedded blocks of tissue from 31 
patients with isolated proliferative disease without atypia were studied. The 
tissue blocks were collected from 1986 through 1992. Each block was given a 
number from PI to P31 with two blocks from the same patient designated ‘a’ 
and ‘b’ . However, it is difficult in this material to assess the true relationship 
between blocks and these blocks may represent independent sites of 
proliferative disease or contiguous disease.
Histological characterisation of PDWA, with particular reference to exclusion 
of atypical ductal hyperplasia, was carried out independently by two 
experienced breast pathologists ( Dr. E.E.A. Mallon & Dr. J.J.Going ) and 
showed absolute concurrence.
Histology on sections from the 37 blocks showed 22 to be predominantly 
moderate PDWA, 11 to be florid PDWA and 4 to be mild.
2.22.Tissue Section Preparation.
Sections, 5 pm thick, from formalin-fixed paraffin-embedded tissue were 
placed on aminopropyltriethoxysilane-treated slides, to avoid the sections 
lifting from the slide during analysis. Before use the slides were baked at 65°C 
for 24 hours. The slides were then dewaxed with xylene (3 washes of 10 min 
each) followed by methanol (2 washes 5 min each). Slides were then digested 
with pepsin (0.4% pepsin in 0.2N hydrochloric acid) for 45 min at 37°C. After 
washing 5 times with distilled water and 5 times in PBS, the slides were post­
fixed in 1% formaldehyde in PBS, 50mM MgCh for 10 mill at room 
temperature (Streck Laboratories, Inc.,Omaha, NE). Finally the sections were 
dehydrated in ethanol.
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2.23. DNA Probes and Probe Labelling.
Chromosome-specific repetitive sequence probes for the following loci were 
purchased from Oncor, Inc. (Gaithersburg, MD):
Chromosome specific repeat sequence centromeric probes were diluted in a 
hybridisation mix consisting of 70% formamide, two times the standard 
concentration of standard saline citrate (SSC) (1XSSC IS 0A5M  NaCl and 
0.0\5 M sodium citrate [ pH 7 ], 500pg / mL salmon sperm DNA, and 10% 
dextran sulphate. These commercial probes were labelled with digoxigenin.
2.24. In-Situ Hybridisation
The chromosome specific digoxigenin labelled probe was added to the tissue 
section, a coverslip applied and sealed with cowgum. For the detection of 
chromosome-specific repetitive sequences, the probe in the hybridisation mix 
and the DNA in a tissue section were denatured together using the .Omnislide 
modular system (Hybaid Ltd, London, U.K.) at 80 °C for 5 minutes.
The probe was then allowed to hybridise to the tissue DNA for 24 hours at 
37°C in a humidity chamber to prevent the slides from drying out.
After hybridisation, the coverslips were removed from the slides in 2 x SSC 
and washed twice in 50% formamide and 1 x SSC at 42°C for 10 minutes and 
twice in 2 x SSC at 42°C for 10 minutes each time.
Prior to immunocytochemical detection, slides were blocked for 30 minutes in 
4 x SSC-TB (4 x SSC, 0.05% Tween 20, and 0.5% Boehringer blocking agent 
(Boehringer Mannheim Corp., Indianapolis, IN.)
D1Z5 (Chromosome 1) 
D3Z1 (Chromosome 3) 
D6Z1 (Chromosome 6)
D10Z1 (Chromosome 10) 
D17Z1 (Chromosome 17) 
D18Z1 (Chromosome 18)
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2.25. Immunocytochemical Detection.
The first detection layer consisted of sheep anti-digoxigenin (sheep anti- 
digoxigenin at 1:200 dilution in 4 x SSC-TB for one hour at room 
temperature) followed by a wash in 4 X SSC-T for 10 min at roon 
temperature.
The second detection layer consisted of donkey anti-sheep fluorescein 
isothiocyanate (FITC) (at 1:300 dilution 4 x SSC-TB for one hour at room 
temperature) followed by a wash of 20 min in 4 x SSC-T at room temperature.
The slides were then dehydrated in ethanol and counterstained with propidium 
iodide (0.4pg/mL) and mounted in antifade medium (Vectashield; Vector 
Laboratories, Inc.).
Fluorescence was analysed on a Bio-Rad (Richmond, CA) MRC-600 laser 
scanning confocal microscope equipped with a krypton argon laser. Original 
unedited images were stored as separate files on optical disks. Images were 
processed using edge enhancement algorithms (Comos Software, Bio-Rad) to 
aid definition of nuclear boundaries and hybridisation sites. Images were 
merged using image Comos and Nexus software (Bio-Rad). Optimal colour 
balance of the pseudocolour images was achieved using image processing 
software, (Photomagic, Micrografx, Arapaho Richardson, Texas, USA).
2.26. ERBB2 / Chromosome 17 Double Hybridisation’s.
2.261.Tissue section preparation was as described before.
2.262.Probe preparation.
ERBB2 and chromosome 17 sequences were detected using the Locus 
Specific Identifier probe (LSI®) Her 2/neu Spectrum Orange™ : CEP® 17
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Spectrum Green ™ (Vysis Inc., Downers Grove, II.). The probe was diluted in 
distilled water and LSI® hybridisation buffer. The probe was then denatured 
separately from the tissue section at 74°C for 5 min.
2.263. In-situ hybridisation.
The tissue sections were denatured in a 70% formamide solution at 80°C for 
5min as previously described, then dehydrated in ice-cold ethanol. The 
denatured probe was then added to the tissue sections, sealed with a coverslip 
and hybridised in a humidity chamber for 24 hours at 37°C. After 
hybridisation, the coverslips were removed from the slides in 2 x SSC and 
washed twice in 50% formamide and 1 x SSC at 42°C for 10 minutes and 
twice in 2 x SSC at 42°C for 10 minutes each time.
As the probe was directly labelled with two fluorochromes no 
immunocytochemical detection was necessary. The slides were therefore 
dehydrated in ethanol and counterstained using DAPI. Fluorescence was 
analysed and images captured using a CCD camera. Original unedited images 
were stored on optical disks
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2.3. Microsatellite Analysis.
2.31. Tumour Samples.
A group of 11 formalin-fixed, paraffin embedded blocks of ductal carcinoma 
in-situ, previously found by interphase cytogenetics to demonstrate 
chromosome 18 loss, was studied. Histology demonstrated the sections to be 
of the comedo, high grade end of the spectrum. Several ducts within each 
section were identified, by an experienced breast pathologist ( Dr.J.J.Going) 
together with a normal terminal duct lobular unit, to act as a normal control.
2.32. Tissue Microdissection.
Sections (5pm) of formalin-fixed, paraffin embedded tissue were cut and 
mounted on untreated glass slides (to aid microdissection), dewaxed in xylene 
and rehydrated. The hydrated sections were stained in 0.1% toluidine blue for 
30 seconds. Each identified duct with DCIS was individually microdissected, 
an approach which ensured a minimum of contamination of normal tissue. 
Tissue microdissection was carried out with the aid of a dissecting microscope 
(model SZ11; Olympus Optical Co., London, U.K.) equipped with a Leitz 
mechanical micromanipulator (type M; Leica Inc., Buffalo,NY.).
2.33. Preparation of Samples and DNA Extraction.
Microdissection was carried out under a drop of proteinase K buffer (lOmM 
Tris and 1 mM EDTA [pH 8.3]), and tissue fragments consisting of individual 
ducts were transferred to a mictocentrifuge tube in 12.5pL or 25pL of the 
same buffer. An equal volume of proteinase K buffer that contained proteinase 
K (lmg/mL) and 1% Tween was then added. After overnight digestion at 
37°C, proteinase K was heat inactivated at 95°C for 10 minutes. Four 
microlitres of this crude DNA lysate was then used for each PCR reaction.
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2.34. PCR Amplification using Chromosome 18 Microsatellites
50pL reactions were performed with 4uL of crude DNA lysate in a reaction 
mixture with 200uM of each dNTP, 2 oligonucleotide primers at 200nmol 
each, 0.2 units of Taq polymerase (Boehringer Mannheim, U.K.) supplied 
with Buffer (50mM KC1, 20mM Tris-HCl pH 8.3, 5mM MgC^ ) and lpCi 
[ P] deoxycytidine triphosphate.
All reaction were conducted in a Hybaid Omnigene PCR thermal cycler using 
a touchdown PCR protocol as follows :
95°C 4 minutes 1 cycle
95°C 1 minute
52 - 62°C 2 minutes —  3 cycles
72°C 30 seconds —
95°C 1 minute
52 - 62°C 2 minutes —  3 cycles
72°C 30 seconds —
95°C 40 seconds
52 - 62°C 30 seconds —  30 cycles
72°C 30 seconds __
72°C 4 minutes 1 cycle
The annealing temperatures were varied to give the best amplification at 
highest stringency for each of the amplimers used. The amplimers were 
obtained from Research Genetics, Huntsville, Alabama.
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2.35. Separation of PCR Amplified Products.
PCR products were resolved on 6% acrylamide denaturing gels formed using 
20 x 38cm glass plates (Model S2 gel apparatus, Life Technologies, Gibco, 
BRL.) coated / polished with ‘’Mr Sheen” (Beckit & Cowan Products 
Ltd,Hull.). PCR products were loaded with 50% glycerol, 1 x TBE, 0.25% 
bromophenol blue, 0.25% xylene cyanole and electrophoresis was conducted 
at 40°C for 4 hours at 60 Watts. Allelic imbalance was assigned when only the 
complete loss of an allele was observed.
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RESULTS
Chapter 3.
Quantification of FISH.______________________
3.1 Introduction.
The technique of fluorescence in-situ hybridisation is based on the same 
principle as Southern blot analysis, ie, the ability of single-stranded DNA to 
anneal to complementary DNA. As in Southern blot analysis, the target DNA 
is attached to a substrate; in the case of FISH , the target DNA is the nuclear 
DNA of interphase cells. The test probe is labelled, most commonly by 
enzymatic incorporation of biotin or digoxigenin-labelled nucleotides. The 
cellular DNA and the labelled probe are denatured to form single stranded 
DNA. A solution containing the probe DNA is then added to the slide, 
covered and allowed to hybridise. Thereafter, the unbound probe is removed 
by washing steps. The labelled probes are then detected with fluorochromes 
(Fig. 1.)
Fluorescence in-situ hybridisation [ FISH ]
1111 II
To  tttttt
DNA accessible DNA probe
Fluorochrome
Fluorescent 
microscopy
< $ ?
FISH image
Figure. 1. Schematic Representation of FISH.
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3.2. Quantification of Hybridisation Signals.
Chromosome -specific centromeric probes were hybridised to sections of 
normal breast tissue and sections of PDWA. The evaluation and interpretation 
of FISH signals were carried out as described by Murphy et al., (Murphy et al. 
1995) in which overlapping nuclei were not analysed, minor hybridisation 
signals identifiable by their low intensity and smaller spot area compared with 
optimal hybridisation’s were not counted and fluorescent patches inconsistent 
in shape with hybridisation signals were not counted. Poor quality 
hybridisation’s were not analysed. For each section of PDWA, 200 nuclei 
from an area of PDWA, 200 nuclei from a normal lobule within the section 
and 200 nuclei from a normal breast section, included in each experiment as 
an external control, were counted.
This information was recorded in frequency-distribution table, and examples 
are shown in Table 1, which shows examples of the frequency of hybridisation 
sites for chromosome 1 on four sections of normal breast tissue. Table 1, 
shows the analysis of the number of hybridisation’s per nucleus for 
chromosomes 1 in normal breast tissue, while (Table 2), shows the basic 
statistical analysis of the hybridisation data presented in Table 1 . The data 
documented in Table 1 are represented in (Figure 2), which show the 
frequency distribution of the number of hybridisation sites per nucleus. As can 
be seen from (Figure 2), 60% to 70% of the nuclei in normal tissue sections 
show two hybridisation signals. The majority of other nuclei have either one or 
no hybridisation signals. This observation is due to nuclear truncation during 
sectioning, (Figure 3).
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of 
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Sample
Number of hybridisations / nucleus
0 1 2 3 4
normal breast 1 28 48 144 4 0
normal breast 2 21 36 151 6 0
normal breast 3 30 56 132 4 0
normal breast 4 18 38 141 3 0
Table 1. Chromosome 1 Copy Number in Normal Breast Tissue
Sample N mean median SDEV SE Range
normal breast 1 224 1.55 2 0.73 0.05 0 1 U>
normal breast 2 214 1.66 2 0.69 0.05 0 - 3
normal breast 3 222 1.49 2 0.75 0.05 0 - 3
normal breast 4 200 1.64 2 0.66 0.05 0 - 3
Table 2. Statistical Analysis of Chromosome 1 Content
80  
7 0  
60  
50  
40  
30  
20 
10 
0
0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3
Normal 1 Normal 2 Normal 3 Normal 4
NUMBER OF HYBRIDISATIONS PER NUCLEUS
Figure.2. Frequency distribution of chromosome 1 hybridisation 
signals in sections of 4 normal breast sections.
cut 5 u m
cut
7 - 8  um
Figure 3. Schematic representation of how 5pm sectioning of paraffin 
sections can lead to nuclear truncation and loss of a predictable 
percentage of hybridisation signals from normal breast tissue.
The hybridisation data were analysed in two ways to assess the degree of 
chromosome imbalance for each section and each chromosome: The 
chromosome index and the signal distribution.
3.21. Chromosome Index. [Cl]
The chromosome index is calculated by dividing the total number of 
hybidisation signals by the total number of nuclei counted. The chromosome 
index gives an average chromosome copy number and is therefore better 
suited to describe clonal changes within a tumour.
50 hybridisations were carried out on normal breast sections, using 
centromeric probes for chromosomes 1, 3, 6, 10, 17 and 18. The chromosome 
indices were calculated and the mean chromosome index for normal breast 
tissue was 1.55 and three standard deviations from the mean gave values of 
1.33 and 1.69.
When using the chromosome index as a measure for chromosome imbalances 
any section with a Cl >1.69 was defined as polysomic and a CI< 1.33 was 
defined as monosomic.
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3.22. Signal Distribution.
The second method that can be used to define chromosome polysomy or 
monosomy is the signal distribution. A section was defined as polysomic for a 
given chromosome if the percentage of nuclei with >2 hybridisation signals 
was >10% of the nuclei counted. A section was defined as monosomic if the 
percentage of nuclei with fewer than two hybridisation signals was >60% of 
the nuclei counted. The analysis of signal distribution can potentially detect 
relatively small populations of cells with numerical chromosome imbalances, 
(Figure 4).
These criteria for both signal distribution and chromosome index are based on 
published estimates and the considerable experience of our group and takes 
into account nuclear truncation.
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Figure 4. Graphic Representation of Polysomy and Monosomy as 
Defined by the Signal Distribution of a Section.
Chapter 4
Chromosomal Imbalances in Proliferative Disease 
Without Atypia [ PDWA ]
4.1. Introduction.
Substantial evidence exists to support the view that a fundamental feature of 
breast cancer evolution is the accumulation of multiple genetic events, which 
have also been demonstrated in DCIS. However, evidence of such alterations 
in PDWA or ADH is lacking. If the evolution from a premalignant lesion to 
the malignant phenotype is accompanied by molecular alterations, 
characterisation of such genetic changes should reinforce the recognition of 
proliferative disease as a premalignant stage.
4.2. Characterisation of Genetic Alterations in PDWA.
Previously our group have shown alterations to chromosomes 1,3, 10, 17 and 
18 in sections of ductal carcinoma in-situ (Murphy et al. 1995), therefore 
chromosome-specific repetitive sequence probes for those chromosomes were 
hybridised to sections of PDWA together with a chromosome 6 probe which 
demonstrated little deviation from normal in DCIS. Figure. 1, shows an 
example of a section of PDWA hybridised with a chromosome 18 probe and 
shows both a high and low power image of a small PDWA lesion and a 
normal lobule which acts as the internal control. Figure 1, demonstrates the 
retention of spacial relationships that FISH affords, which allows the 
cytogenetic images and data to be directly compared to the original histology. 
Sections hybridised to centromeric probes specific for chromosomes 1, 3, 6, 
10, 17 and 18 were analysed as previously described [see Chapter '3] and the 
chromosome index and signal distribution for each PDWA lesion and its 
internal and external control determined. The data for both chromosome index 
and signal distribution are presented in (Table la  & b). This table presents the 
chromosome index of the sections and the percentage of nuclei with <2
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proliferative duct normal lobule
x60
Figure 1. Analysis of PDWA bv FISH.
[A] Low power image of a section stained with H&E. A serial 
section was then used for FISH. [B] & [C] Low power image of 
a section that has undergone FISH using a chromosome 18- 
specific probe. Image shows propidium iodide staining of the 
nuclei. Area [B] is a region of PDWA and a high power image 
of the hybridisation is shown in [D]. [C] is a normal lobule as 
confirmed by examination of the H&E and a high power image 
of the hybridisation is shown in [E]. Analysis of the PDW A 
lesion showed it to have a loss of chromosome 18 sequences in 
comparison to the normal lobule.
Chrom osom e
10
Cl <2 >2
1.47 45 0
1.56 33 0
1.58 34 0
1.43 51 2
1.49 43 2
1.49 43 2
1.49 43 2
1.44 45 0
1.61 35 3
1.64 31 2
1.48 39 0
1.35 51 0
1.62 36 0
1.21 65 1
1.58 34 1
1.44 44 1
1.52 36 0
1.49 42 2
1.41 47 2
1.59 36 1
1.42 44 0
1.51 38 0
1.35 51 0
1.49 43 0
1.51 37 0
1.34 57 0
1.23 59 0
1.57 39 1
1.28 64 0
1.58 48 1
1.58 48 1
1.52 38 0
1.42 45 1
1.51 42 1
1.32 52 0
1.30 52 0
1.49 50 2
No. section Chromosome
18
Chromosome
17
Cl <2 >2 Cl <2 >2
1 9137 1.29 63 1 1.57 37 2
2 4700eb 1.51 44 0 1.48 41 0
3 5344a 1.48 42 0 1.64 37 7
4a 7303e 1.41 52 1 1.71 33 11
4b 7303f 1.52 38 1 1.52 38 2
5 6828 1.52 38 1 1.52 38 2
6 5390 1.52 38 1 1.52 38 2
7 7302b 1.47 46 3 1.53 44 6
8 0813c 1.6 34 1 1.75 32 11
9 7667a3 1.48 39 1 1.46 47 2
10a 9041k 1.59 33 0 1.55 41 0
10b 904 lh 1.6 36 2 1.8 29 13
11a 4655b 1.68 30 4 1.63 33 3
l i b 4655a 1.58 36 0 1.61 36 1
12 0881 1.5 41 1 1.64 36 3
13 6642 1.34 52 0 1.46 45 1
14 5520 1.54 41 1 1.49 38 1
15 2641a 1.59 34 1 1.8 32 15
16 1 1 158 1.55 38 0 1.55 40 1
17 8429 1.5 40 1 1.34 51 0
18 7882 1.47 42 1 1.58 41 8
19 3593a 1.44 48 1.34 54 0
20 10605 1.44 46 0 1.63 31 2
21 5060ae 1.04 76 0 1.61 35 2
22 8062 1.27 59 0 1.51 40 1
23a 6913e 1.26 57 0 1.49 39 0
23b 6 9 13f 1.18 67 1.52 39 0
24 4093b 0.97 81 0 1.86 25 21
25a 6190a5 1.52 38 1 1.59 33 0
25b 6 190a9 1.54 38 0 1.58 33 2
26 5644 1.30 38 0 1.58 33 2
27 6834 1.47 44 0 1.6 34 2
28 8430 1.29 56 0 1.55 36 2
29 3804 1.22 65 0 1.6 36 0
30 1 1403 1.59 34 1.39 45 0
31a 3893g 1.45 44 0 1.44 49 0
31b 3893h 1.32 52 0 1.36 44 0
Table 1 [a]. Chromosome Index and Signal Distribution Data for Sections 
of PDWA.( Sections with a Gain or Loss are Highlighted in yellow, while 
sections showing a tendency to a Gain or loss are highlighted in pink.)
Chrom osom e
3
C l <2 >2
1.43 45 1
1.42 44 0
1.42 45 1
1.49 39 1
1.51 41 0
1.51 41 0
1.51 41 0
1.48 40 0
1.3 57 0
1.62 31 2
1.63 36 1
1.74 33 18
1.45 44 2
1.33 56 1
1.47 43 1
1.68 31 7
1.39 47 0
1.32 52 0
1.3 56 0
1.52 39 1
1.62 38 8
1.66 33 9
1.5 39 0
1.38 51 0
1.41 44 0
1.53 38 1
1.42 46 0
1.49 38 0
1.58 36 2
1.46 45 2
1.46 45 2
1.27 38 3
1.55 37 2
1.79 29 12
1.47 43 3
1.47 41 2
1.37 49 0
No sections C hrom osom e
6
C l <2 >2
1 9137 1.41 48 4
2 4700eb 1.35 50 0
3 5344a 1.44 45 0
4a 7303e 1.64 33 2
4b 7303f 1.52 37 1
5 6828 1.52 37 1
6 5390 1.52 37 1
7 7302b 1.4 48 0
8 0813c 1.52 41 0
9 7667a3 1.33 54 1
10a 9041k 1.64 30 1
10b 904 lh 1.52 44 1
1 la 4655b 1.55 38 3
l i b 4655a 1.46 47 0
12 0881 1.63 30 1
13 6642 1.51 42 0
14 5520 1.43 44 0
15 2641a 1.52 37 1
16 11 158 1.38 48 0
17 8429 1.62 31 0
18 7882 1.48 44 0
19 3593a 1.59 33 0
20 10605 1.47 41 0
21 5060aeb 1.35 52 0
22 8062 1.43 44 1
23a 6913e 1.57 38 3
23b 6913 f 1.42 46 0
24 4093b 1.63 37 5
25a 6190a5 1.59 37 0
25b 6190a9 1.45 46 0
26 5644 1.28 | 46 0
27 6834 1.42 47 0
28 8430 1.42 48 0
29 3804 1.59 35 0
30 1 1403 1.45 43 0
31a 3893g 1.29 53 0
31b 3893h 1.46 45 1
Chrom osom e
1
C l <2 >2
1.6 40 1
1.56 35 1
1.32 54 0
1.32 52 0
1.33 57 0
1.33 57 0
1.33 57 0
1.52 40 0
1.61 35 5
1.38 48 0
1.47 45 1
1.42 45 0
1.41 49 1
1.43 45 2
1.6 33 1
1.59 33 0
1.58 35 3
1.3 | 56 1
1.46 45 0
1.3 | 55 0
1.43 45 0
1.4 47 2
1.41 48 1
1.59 35 2
1.3 | 55 0
1.51 38 2
1.53 37 0
1.37 53 2
1.24 61 0
1.29 59 0
1.29 59 0
1.4 46 0
1.58 33 1
1.35 49 1
1.37 47 0
1.28 55 0
1.39 46 1
Table 1 [b]. Chrom osom e Index and Signal D istribution D ata for 
Sections of PDWA. ( Sections with a G ain  o r  Loss are  Highlighted in 
yellow, while sections showing a tendency to a Loss o r  G ain  are  
highlighted in pink).
hybridisation signals and the percentage of nuclei with > 2 hybridisation 
signals.
The chromosome index is a direct method of analysing chromosomal 
imbalances and allows a comparison of the average chromosome copy number 
for each PDWA lesion to be made. The chromosome index data for each 
centromeric probe are presented in Figure. 2 (i - vi) which include the Cl’s of 
50 normal breast sections from which the mean chromosome index was 
calculated; the Cl’s for each section of PDWA and the Cl’s for the normal 
controls of each PDWA showing a deviation from normal. When the 
chromosome index data are summarised together, (Figure.3), it is apparent that 
the majority of PDWA sections are within the normal range, [see Chapter 3]. 
However, a pattern begins to emerge of a subpopulation of PDWA which are 
showing a low frequency of chromosomal imbalances. For example, from 
(Figure 3), a subset of of PDWA sections show gains in the frequency of 
centromeric markers for chromosomes 3 and 17, wherf compared to normal 
tissue; whereas loss of centromeric markers for chromosomes 1,10 and 18 are 
found in a small population of PDWA. Chromosome 6 showed little deviation 
from the internal and external controls.
In order to quantify chromosome imbalances in more detail the signal 
distribution of each section was analysed, which is more sensitive at 
identifying small populations of cells, within a section, with imbalances. 
These chromosome imbalances may be missed by the chromosome index, 
which is a measure of the average chromosome copy number of all cells 
within a duct. Hence, chromosomal loss or gain was assigned only if both 
criteria (chromosome index and signal distribution) indicated an imbalance. If 
only one criterion was met, the section was recorded as showing a tendency to 
a loss or gain. Using this criteria, the frequency of chromosomal imbalances 
was calculated and is demonstrated in (Table 2). The data shown in (Table 2) 
resembles the low frequency pattern of chromosomal imbalances presented in 
(Figure 3). Of the 37 sections analysed, it can be seen from (Table 1) and 
(Table 2) that chromosome 18 shows the highest frequency of loss in PDWA
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Figure 2 (i).
Group A
The chromosome indices of 50 normal breast sections analysed by all 
centromeric probes and used to determine the normal range, indicated by
+/- 3sd s.
Group B : External controls.
The chromosome indices of normal breast sections analysed using a 
chromosome 18 centomeric probe.
Group C : Internal controls.
The chromosome indices of normal breast lobules within the sections of 
PDWA.
Group D :
10 sections of PDWA from 31 patients demonstrate a loss of chromosome 
18 sequences.
Chromosome 17
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Figure 2 (ii).
Group A
The chromosome indices of 50 normal breast sections analysed by all 
centromeric probes and used to determine the normal range, indicated by
Group B : External controls.
The chromosome indices of normal breast sections analysed using a 
chromosome 17 centomeric probe.
Group C : Internal controls.
The chromosome indices of normal breast lobules within the sections of 
PDWA.
Group D ;
5 sections of PDWA from 31 patients are demonstrating a gain of 
chromosome 17 centromeric sequences.
Chromosome 10
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Figure 2 (iii)
Group A
The chromosome indices of 50 normal breast sections analysed by all 
centromeric probes and used to determine the normal range, indicated by
+ /-  3 sds.
Group B : External controls.
The chromosome indices of normal breast sections analysed using a 
chromosome 17 centomeric probe.
Group C : Internal controls.
The chromosome indices of normal breast lobules within the sections of 
PDWA.
Group D :
5 sections of PDWA from 31 patients are showing a loss of chromosome 
10 sequences.
Chromosome 6
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Figure 2 ( iv)
Group A
The chromosome indices of §0 normal breast sections analysed by all 
centromeric probes and used to determine the normal range, indicated by
+/- 3sds.
Group B : External controls.
The chromosome indices of normal breast sections analysed using a 
chromosome 17 centomeric probe.
Group C : Internal controls.
The chromosome indices of normal breast lobules within the sections of 
PDWA.
Group D :
2 sections of PDWA from 31 patients are showing a loss of chromosome 6 
sequences.
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Figure 2 ( v)
Group A
The chromosome indices of 50 normal breast sections analysed by all 
centromeric probes and used to determine the normal range, indicated by
+/- 3sds.
Group B : External controls.
The chromosome indices of normal breast sections analysed using a 
chromosome 17 centomeric probe.
Group C : Internal controls.
The chromosome indices of normal breast lobules within the sections of 
PDWA.
Group D :
2 sections of PDWA are showing a gain of chromosome 3 sequences while 
4 sections are showing a loss of chromosome 3 sequences.
Chromosome 1
1.7
1.6
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1.3
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normals Chi internal PDWA 
normal controls
Figure 2 ( v i )
Group A
The chromosome indices of 50 normal breast sections analysed by all 
centromeric probes and used to determine the normal range, indicated by
+/- 3sds.
Group B : External controls.
The chromosome indices of normal breast sections analysed using a 
chromosome 17 centomeric probe.
Group C : Internal controls.
The chromosome indices of normal breast lobules within the sections of 
PDWA.
Group D :
9 sections of PDWA from 31 patients are showing a loss of chromosome 1 
sequences
NQRMAI Chl8 Chl7 ChlO Ch6 Ch3 Chi
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Figure 3. Summary of chromosome index data from normal breast
sections and PDWA. The vast majority of proliferative sections 
lie within the normal range, however a small sub-population are 
demonstrating gains of chromosome 17 and 3 centromeric 
sequences while chromosomes 1,10 and 18 are showing losses of 
centromeric sequences.
Chromosome No. Loss Balanced Gain Total
18 5(5) 32 0 37
17 0 32 5 37
10 2(3) 35 0 37
6 0(2) 37 0 37
3 0(4) 35 2 37
1 1(8) 36 0 37
!
Table 2. Chromosomal Imbalances in Proliferative Disease Without 
Atypia. A sample had to show imbalance by both 
chromosome index and signal distribution to be counted. 
Imbalances determined by either chromosome index or signal 
distribution alone are shown in brackets. [See Chapter 3 for 
details].
The number of alterations in individual lesions ranged from 0 
to 3, with 11 sections showing 2 or more chromosome 
imbalances, (Table 1 and Table 4).
with 5 sections showing a loss of chromosome 18-specific sequences and a 
further 5 sections showing a tendency to a loss, (Figure 1). Chromosomes 1 
and 10 also show a loss. Chromosome 17 shows the highest frequency of gain 
in PDWA with 5 sections demonstrating a gain of chromosome 17-specific 
sequences. (Figure 4) shows a low and high power image of a PDWA section 
with a gain of chromosome 17 sequences. Chromosome 3 also shows a gain of 
chromosome 3 sequences in 2 sections but also the tendency to a loss in a 
further 4 sections.
The number of alterations in individual lesions ranged from 0 to 3, with 11 
sections showing 2 or more chromosome imbalances, (Table land Table 4).
4.3. Analysis of Intratumour Heterogeneity using FISH.
Sections of PDWA clearly show individual regions of disease. Thus, there is 
potential for intratumour heterogeneity. In an attempt to ascertain whether 
heterogeneity exists within sections and whether FISH is sensitive enough to 
detect it, five sections of PDWA were analysed using FISH. In this instance 
the chromosome index and signal distribution of multiple areas of PDWA 
within each section were individually calculated. There was no difference in 
chromosome index or signal distribution between PDWA lesions of the same 
section for the panel of centromeric probes. Data for section 5 are shown in 
(Table3). FISH did not provide any evidence of genetic heterogeneity in this 
instance and indeed this data probably analyses the question of intraobserver 
variation rather than intratumour heterogeneity, hence the adoption of 
microsatellite analysis in Chapter 6 to address the question of intratumour 
heterogeneity in sections of DCIS.
4.4. Florid versus Non-Florid PDWA.
The identification of specific molecular alterations within specimens of 
PDWA prompted us to examine the relationship between histology and 
chromosomal abnormalities in more detail. The PDWA group was therefore 
split into biopsies with florid hyperplasia versus mild to moderate hyperplasia,
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Figure 4. Section of PDWA demonstrating a gain of 
chromosome 17 sequences.
[A] Low power image of a section of PDWA that has undergone 
FISH using a chromosome 17-specific probe . Image shows 
propidium iodide staining of the nuclei.
[B] Is a high power image of the region of PDWA shown above. 
The boxed nuclei are examples of nuclei with >2 hybridisation 
signals.
Section 5 Number of hybridisations Cl
0 1 2 3 Total
A 22 35 141 2 200 1.45
B 18 53 129 0 200 1.41
C 28 34 135 3 200 1.49
D 24 45 131 0 200 1.40
E 29 44 125 2 200 1.37
Table 3. Chromosome 18 Copy Number and Chromosome Index in 
multiple areas of PDWA, Within Section 5. (A -E represent 
data from different foci of PDWA)
Sections Pathology Chromosome Imbalances
PI mild pdwa C h l8 i
P2 mild pdwa
P3 mild pdwa tC h li)
P4a mild pdwa C h l7 t (C h li)
P4b moderate pdwa (C h li)
P5 moderate pdwa
P6 moderate pdwa
P7 moderate pdwa
P8 moderate pdwa C h l7 t (C h3i)
P9 moderate pdwa
PlOa moderate pdwa
PlOb moderate pdwa ChI7T Ch3?
P lla moderate pdwa
P llb moderate pdwa C h ld i
P12 moderate pdwa
P13 moderate pdwa
P14 moderate pdwa
P15 moderate pdwa (C h3i C h li)
P16 moderate pdwa (C h3i)
P17 moderate pdwa (Chl i )
P18 moderate pdwa
P19 moderate pdwa
P20 moderate pdwa
P21 moderate pdwa C h is i
P22 moderate pdwa (Chl8sl C h li)
P23a moderate pdwa K 'hlS i)
P23b florid pdwa C h i8 i  (C hio i )
P24 florid pdwa C h l8 i C h l7 t
P25a florid pdwa C h ld i C h l i
P25b florid pdwa (C h li)
P26 florid pdwa (C h l8 i C h 6 iC h li)
P27 florid pdwa (C h3i)
P28 florid pdwa (C his i )
P29 florid pdwa C h i8 i Ch3?
P30 florid pdwa (C hld i)
P31a florid pdwa (C h ld i C hbi C h li)
P31b florid pdwa (C h l8 i)
Table 4. Summary of Chromosome Imbalances in Proliferative Disease
without Atypia. Chromosomal gains or losses are in red type. 
Chromosomes. (Ch). showing a trend to loss or gain are shown in 
brackets.
(Table 4 and Table5). A total of 19 chromosome imbalances (chromosomal 
loss or gain plus a tendency to a loss or gain) were shown in the 11 cases of 
florid PDWA and 19 chromosomal imbalances were shown in the 26 cases of 
non-florid PDWA, (Table 4 and Table 5). Applying a two-sided Mann- 
Whitney test to compare the number of genetic changes between the florid and 
non-florid PDWA demonstrated a significant difference between the two 
groups, (p=0.006), therefore florid PDWA is associated with a higher 
frequency of chromosomal imbalances than non-florid within our study group.
Number of 
chromosome 
imbalances 
per section
Non-florid
PDWA
Florid
PDWA
0 13 (50%) 0 (0%)
1 8(31%) 5 (45.5%)
2 4(15%) 5 (45.5%)
3 1 (4%) 1 (9%)
No. = 26 No. = 11
Table 5. Comparison of Genetic Alterations Between Florid 
and Non-Florid PDWA.
4.5. Discussion.
We have used interphase cytogenetics to analyse chromosomal imbalances in 
PDWA. Using this approach our group previously identified a high frequency 
of imbalances in DCIS involving particularly chromosomes 1, 3, 10, 17 and 
18. The pattern of chromosomal imbalances identified in PDWA mirrored that 
found in DCIS but at a reduced frequency, (Figure 5). Loss of chromosome 1,
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10 and 18 centromeric sequences were common to both PDWA and DCIS as 
was gain of chromosome 3 and 17 centromeric sequences. Chromosome 6 
showed little deviation from normal in either group. Thus we may be 
identifying genetic alterations in a sub-population of PDWA which confers a 
greater propensity toward progression, (see Figure 5). The histological 
examination of benign breast biopsies and subsequent clinical follow-up has 
identified a number of risk categories for the subsequent development of 
invasive carcinoma. Thus, PDWA is associated with a slight risk while DCIS 
is associated with a high risk. However, although this may be useful in the 
clinical setting for prognostication, the histological stratification is largely 
descriptive rather than mechanistic. Within this stratification of risk, wide 
confidence limits are assigned to each group suggesting the magnitude of risk 
for each individual within a group can vary, and indeed some individuals may 
in fact have a higher risk than predicted by histology alone.
Interestingly, within the PDWA specimens, the molecular alterations 
associated with florid PDWA rather than non-florid PDWA, (p=0.006), Table 
5. These data identify the first molecular alterations distinguishing florid from 
non-florid PDWA, and suggest the transition to DCIS is associated 'with these 
same alterations, (Figure 5). Thus, the molecular events may identify 
individuals with PDWA with a high risk for invasive cancer than can be 
attributed by histological examination alone. The identification of 
chromosomal imbalances common to both PDWA and DCIS sets an agenda 
for the further molecular investigation into early breast cancer progression.
When the frequency of chromosomal imbalances and ERBB2 amplification 
[see Chapter 5] are compared between PDWA and DCIS (Figure 5), it is 
evident that there is a large increase in the frequency of chromosomal 
imbalances affecting chromosome 3 and chromosome 17 between PDWA and 
DCIS suggesting loci responsible for the progression of PDWA to DCIS may 
be present on those chromosomes. This pattern is also present for chromosome 
10 but to a lesser extent. In contrast the frequency of chromosomal imbalances 
affecting chromosome 18 remain relatively constant, which may imply loci
49
involved in the earliest stage of breast cancer progression are present on 
chromosome 18. Hence, the necessity to identify regional alterations on 
chromosome 18 [see Chapter 6].
Particularly striking however is the large increase in the frequency of 
chromosome alterations to chromosome 3 and chromosome 17 between 
PDWA and DCIS suggesting that those chromosomes may harbour loci 
responsible for the progression of PDWA to DCIS.
Our group have recently mapped the human telomerase RNA gene; (hTR), to 
chromosome 3q26.6 and have demonstrated the hTR gene to be amplified in a 
number of solid tumours and a putative telomerase repressor has been 
localised to 3p. (Soder et al. 1997) While there is no evidence to suggest that 
telomerase is essential for normal cellular proliferation, the reactivation of 
telomerase activity may be a fundamental feature of progression to the 
malignant phenotype. (Parkinson, 1996) A study combining FISH analysis and 
microsatellite analysis of microdissected DCIS and PDWA should define 
whether this locus is subject to amplification or regional deletions in pre- 
invasive disease.
Chromosome 17 and loci on chromosome 17 are frequently altered in invasive 
breast cancer and DCIS. This data suggests that chromosome 17 alterations 
may already be present in PDWA and that progression to DCIS involves an 
increase in chromosome 17 alterations and the development of ERBB2 
amplification, (Figure 5) [see Chapter 5].
In summary, interphase cytogenetics has identified chromosomal alterations in 
PDWA which parallel those found in DCIS, providing strong evidence that 
PDWA is a true precursor of DCIS and invasive cancer. An interesting 
extension to this work will be to analyse sections of ADH to determine 
whether or not they share the same chromosomal imbalances as PDWA and 
DCIS and may provide valuable molecular data which could help validate or
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repudiate the distinction usually drawn between ADH and low grade DCIS, 
which is an area of pathological and clinical difficulty.
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Chapter 5.
Interphase Cytogenetic Analysis of the ERBB2Gene.
5.1. Introduction.
ERBB2 amplification has been described to occur at a high frequency in DCIS 
and indeed our group have previously shown by interphase cytogenetics that 
ERBB2 amplification occurs in 27% of DCIS which is a slightly lower figure 
than those quoted by other authors.(Liu et al. 1992; Hubbard et al. 1994; 
Murphy et al. 1995; Allred et al. 1992) However, benign breast disease in 
general has not been associated with amplification of this oncogene (Allred et 
al. 1993). The gene is localised to 17q21.
5.2. ERBB2 / Chromosome 17 Analysis of PDWA.
To determine whether PDWA is associated with amplification of ERBB2, 37 
sections of PDWA ( previously analysed by centromeric probes, Chapter 4) 
were analysed using double hybridisation’s to simultaneously detect ERBB2 
sequences and chromosome 17 centromeric sequences. Hence, chromosome 
17 polysomy masquerading as ERBB2 amplification can be detected and 
provides a more accurate measure of amplification.
No ERBB2 amplification was observed in our PDWA sections.
Due to the high quality of hybridisation of the ERBB2 / C hi7 probe, single 
copies of ERBB2 were easily identified, therefore it was possible to analyse 
regional alterations to chromosome 17 at the ERBB2 locus in 17 sections of 
PDWA. Included in these 17 sections were two shown to have gain of 
chromosome 17-specific centromeric sequences, ( Chapter 4, Table 1 and 
Table 2, P4a & P8). The sections P4a & P8 have been renamed sections 5 & 
15 respectively for the purposes of this analysis. The remaining 15 sections did
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Nuclei with two copies 
of chromosome 17 & 
two copies of ERBB2
Figure 1. ERBB2 / Chromosome 17 double hybridisation of a 
section of PDWA .
The nuclei of the section of PDWA are pseudocoloured blue; the 
ERBB2 hybridisation signals are red; and the chromosome 17 
hybridisation signals are green. Analysis showed that the 
section had a normal copy number of ERBB2 and Chromosome 
17 sequences.
not demonstrate chromosome 17 imbalances. (Figure 1) provides an 
illustration of a ERBB2 / Chi 7 double hybridisation for a section of PDWA. 
The chromosome index and the signal distribution were determined as 
previously described, for each section of PDWA and an area of normal tissue 
within each section. The number of ERBB2 hybridisation signals and the 
number of the chromosome 17 hybridisation signals were counted in the same 
200 nuclei per section. The data for the chromosome indices and signal 
distributions are presented in (Tables 1 to 4) and the chromosome index for 
each PDWA section and it’s normal control are graphically displayed in 
(Figure 2). The data confirmed that no increased copy number of ERBB2 was 
found and this was confirmed using the Mann-Whitney test to compare the 
ERBB2 hybridisations of normal tissue to those of PDWA (p=0.45).
This comparison of the two probes is possible because the efficiency of each 
probe is similar as is demonstrated in (Figure 2), (Mann Whitney, p = 0.33), 
where the chromosome index for normal and PDWA Sections all lie within, 
previously defined normal limits [see Chapter 3]. The experiment also 
reproduced the gain of chromosome 17 sequences in sections 5 and 15, (Table 
2), however, this was not accompanied by an increased copy number of 
ERBB2, (Figure 3).
5.3. ERBB2 / Chromosome 17 Analysis of Recurrent DCIS.
To determine whether recurrent DCIS is associated with a higher frequency of 
ERBB2 amplification, a small group of patients were identified in whom 
initial and recurrent DCIS tissue blocks were available.
Ten patients were identified who had undergone initial wide local excisions 
for DCIS + /- radiotherapy. All patients had a recurrence of DCIS within 5 
years and four recurrences had an invasive component. All patients underwent 
a modified radical mastectomy and axillary clearance in whom an invasive 
component had been identified and a simple mastectomy if only DCIS was 
present. Thankfully this is not a large population to study as they probably 
represent treatment failure.
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Chromosome 17 normals
No section Cl <2 >2
1 5344 1.42 46 0
2 7822 1.47 40 1
3 6832 1.38 48 0
4 3593 1.39 50 0
5 3804 1.45 40 0
6 842 1.52 37 1
7 8062 1.49 41 0
8 8430 1.49 41 1
9 0881 1.51 39 1
10 9137 1.52 39 1
11 5520 1.54 39 0
12 7302 1.51 40 0
13 3893 1.37 50 0
14 2641 1.41 47 0
15 0813 1.46 44 0
16 6828 1.49 46 0
17 5390 1.43 49 0
Chromosome 17 PDWA
No section Cl <2 >2
1 5344 1.37 50 0
2 7822 1.42 49 1
3 6832 1.38 46 1
4 3593 1.43 47 0
5 3804 1.61 37 12
6 842 1.43 44 0
7 8062 1.36 49 1
8 8430 1.43 44 1
9 0881 1.38 47 0
10 9137 1.39 50 0
11 5520 1.43 45 0
12 7302 1.47 44 1
13 3893 1.40 48 0
14 2641 1.51 39 0
15 0813 1.61 35 14
16 6828 1.48 48 0
17 5390 1.49 49 0
Table 1.
ERBB2 normals 
No section Cl <2 >2
Table 2.
ERBB2 PDWA
No section Cl <2 >2
1 5344 1.55 37 0
2 7822 1.41 48 1
3 6832 1.5 43 1
4 3593 1.48 40 0
5 3804 1.49 41 1
6 842 1.45 43 0
7 8062 1.55 37 0
8 8430 1.40 48 0
9 0881 1.48 41 1
10 9137 1.47 43 0
1 1 5520 1.47 42 0
12 7302 1.45 43 1
13 3893 1.45 40 0
14 2641 1.47 43 1
15 0813 1.49 44 1
16 6828 1.57 36 0
17 5390 1.50 41 0
1 5344 1.48 43 0
2 7822 1.44 45 0
3 6832 1.52 41 0
4 3593 1.46 42 2
5 3804 1.55 40 1
6 842 1.5 35 0
7 8062 1.40 48 1
8 8430 1.54 38 1
9 0881 1.39 49 0
10 9137 1.54 39 2
11 5520 1.49 44 0
12 7302 1.45 41 1
13 3893 1.48 34 1
14 2641 1.5 44 0
15 0813 1.53 42 0
16 6828 1.44 41 0
17 5390 1.43 38 0
Table 3. Table 4.
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Figure 2. Graphic representation of the chromosome indices of ERBB2 
Chromosome 17 hybridisations of 17 PDWA sections and their 
normal controls. This demonstrates the efficiency of each 
probe is similar and thus the results are comparable.
N
o.
 o
f 
N
uc
le
i 
wi
th
 
> 
2 
H
yb
ri
di
sa
tio
n 
Si
gn
al
s
ERBB2 Chi 7 FRBB2 C h l7
Section 5 Section 15
■  ERBB2
C hrom osom e 17
Figure 3. PDWA Sections 5 and 15 Demonstrating Polysomy of 
Chromosome 17 without Increased Copy Number of 
ERBB2.
Paraffin-embedded, formalin-fixed sections were prepared and analysed as 
previously described [see Materials and Methods].An example of a ERBB2 / 
Chromosome 17 hybridisation is presented in (Figure 4), which demonstrates 
ERBB2 amplification in the tumour cells within the duct, but only single copy 
of ERBB2 and chromosome 17 in the normal myoepithelial cells surrounding 
the duct.
The results of the ERBB2 / chromosome 17 hybridisation’s are presented in 
(Table 5) . Two of the ten initial samples of DCIS showed amplification of 
ERBB2. The recurrent biopsies of those patients whose initial biopsy 
demonstrated ERBB2 amplification also showed amplification of the ERBB2 
oncogene. There was no other evidence of amplification in the remainder of 
the recurrent biopsies, thus our small group of recurrent DCIS had the same 
frequency of ERBB2 amplification as the group of initial biopsies. Of the two 
recurrences with amplification one had an invasive component and one did 
not. ERBB2 amplification was demonstrated in both the DCIS and invasive 
component of the recurrence.
5.4. Discussion.
Analysis of ERBB2 has established that PDWA is not associated with 
amplification of this oncogene, however our data suggests that chromosome 
17 alterations are already present in PDWA and that progression to DCIS 
involves an increase in the frequency of chromosome 17 alterations and the 
development of ERBB2 amplification.
The analysis of recurrent DCIS implies that ERBB2 amplification is not 
associated with the development of recurrent disease and that it is the 
persistence of an established subclone of DCIS, with existing genetic 
alterations, that results in recurrences, probably due to inadequate excision. In 
addition, ERBB2 does not seem to be crucial in the development of invasive 
cancer in the recurrences, as three DCIS recurrences with invasion did not 
show amplification of the ERBB2 oncogene.
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[ A ] Schematic diagram of a duct with 
DCIS.Within the w hite line ( basement 
membrane), are the tumour cells, and 
those cells outwith the line are normal 
myoepithelial cells.
Figure 4. The FISH image is an example of an ERBB2 / 
Chromosome 17 double hybridisation.
The nuclei are pseudocoloured blue; the ERBB2 hybridisations 
are red and the chromosome 17 hybridisations are green. The 
tumour cells are demonstrating amplification of ERBB2 while 
the normal peripheral myoepithelial cells are demonstrating 
normal copy number for ERBB2 and chromosome 17.
Section Initial Biopsy 
Pathology
ERBB2
amplification
Recurrent Biopsy 
Pathology
ERBB2
amplification
1 DCIS DCIS / INVASIVE
2 DCIS - DCIS -
3 DCIS - DCIS -
4 DCIS - DCIS / INVASIVE -
5 DCIS AMP DCIS / INVASIVE AMP
6 DCIS - DCIS -
7 DCIS - DCIS -
8 DCIS AMP DCIS AMP
9 DCIS - DCIS -
10 DCIS - DCIS / INVASIVE -
Table 5. Results of ERBB2 amplification analysis on initial and 
recurrent DCIS.
The finding of polysomy of chromosome 17 for a section of PDWA associated 
with a normal ERBB2 copy number is particularly interesting because it infers 
that a regional deletion encompassing the ERBB2 locus on chromosome 17, 
with subsequent reduplication of chromosome 17 is present in these PDWA 
lesions, (Figure 5), a situation previously observed in DCIS using LOH 
analysis (Murphy et al. 1995).
This interpretation of the FISH data is in keeping with the model of the genetic 
evolution of breast cancer by Dutrillaux and Devillee, (Figure 6). This model 
envisages two phases, the first of which suggests that genetic instability is 
initiated by mutations to a crucial gene or genes. In this phase, structural 
chromosomal rearrangements are thought to be crucial and would be 
associated with loss of heterozygosity and chromosome losses, as well as 
leading to DNA amplification. This hypodiploid clone would then enter phase 
two which involves endoreduplication which is thought to confer a growth 
advantage to the resultant clone because of a gene dosage phenomenon. A 
single aneuploid clone may arise or more likely several subclones including 
the origonal hypodiploid clone would persist. The identification of genetic 
changes in PDWA consistent with the presence of a hypotetraploid clone 
suggests that the process of endoreduplication may occur earlier in breast 
cancer progression than was proposed in Figure 6.
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Figure 5. Schematic representation of the mechanism by which a PDWA 
lesion can have increased copy number of chromosome 17 but a 
normal copy number of a regional m arker such as ERBB2.
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Figure 6. Genetic Model of Breast Cancer Evolution.
( Modified from Cornelisse & Devilee 1990)
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Chapter 6
Identification of Chromosome 18 Imbalances in 
Ductal Carcinoma in-situ.
6.1. Introduction.
Molecular studies have demonstrated a number of chromosomes which may 
harbour key genes involved in the progression of breast cancer. It is 
hypothesised that genetic alterations important for tumour progression are 
produced early in development and that progression related genetic events or 
randomly acquired alterations are probably generated later. Hence, the 
molecular analysis of pre-invasive breast lesions should lead to the discovery 
of genetic alterations crucial to the early stages of breast cancer initiation and 
progression.
A striking feature of the interphase cytogenetic analysis of these pre-invasive 
lesions is the high frequency of chromosome 18 loss in both DCIS and 
PDWA. LOH studies of invasive breast cancer and DCIS have also 
demonstrated a high frequency of LOH in chromosome 18 (James et al 1997; 
Stratton et al. 1995; Aldaz et al. 1995; Murphy et al. 1995; Fujii et al. 1996; 
Allred et al. 1993; Harrison et al. 1995; Radford et al. 1995). Thus, 
chromosome 18 may harbour loci involved in the earliest stages of breast 
cancer progression or that a subset of lesions may progress via this route. 
Hence, there is a need to study chromosome 18 in more detail, using 
microsatellite analysis, in order to identify regional changes on chromosome 
18.
Three polymorphic DNA markers were chosen to analyse chromosome 18. 
Two on the p-arm (D18S59 & D18S71), chosen due to the paucity of 
information about this arm and one from the q-arm (D18S70), chosen because 
a high frequency of LOH that has been found at this locus (18q23) in invasive 
breast and other cancers,(Huang et al.1995, Devilee et al. 1991), (Figure 1).
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Chromosome 18
11.32
11.31
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11.1
11.2
12.1
12.2
12.3 
21.1 
21.2
21.3
22
D18S59 (18pl 1.32)
D18S71 (18pll.22)
DCC (18q21.1) 
DPC-4 (18q21.1) 
BCL-2 (18q21.3)
23 D18S70 (18q23)
Figure 1. Chromosome 18 ideogram illustrating the position of the 
polymorphic DNA markers. Genes proposed to be 
involved in breast carcinogenesis are also included, 
(DCC, DPC4).
A number of molecular studies now indicate that DCIS may exhibit 
intratumour genetic heterogeneity whereby individual foci of DCIS, from the 
same patient, show differing patterns of allellic imbalances (Fujii et al. 1996).
Thus, in order to identify regional alterations of chromosome 18 and to 
address the phenomenon of intratumour heterogeneity of DCIS microsatellite 
analysis was performed, using three polymorphic markers for chromosome 
18, on 62 individually microdissected foci of DCIS from 11 patients 
previously found to have chromosome 18 loss by interphase cytogenetics, 
(Figure 2).
Microsatellite Analysis
C H I 8 C d  electrophoresis 
of PCR products
normal
section
deis
microdissected
tissue
isolated
DNA
status of 
alleles
A
B
Figure.2. Strategy for Determining the Allelic Status of Chromosome 18.
Foci o f ductal carcinoma in-situ and normal tissue were separated by 
m icrodissection of routine histological sections from resected breast 
specimens. Total genomic DNA was isolated from each sample. The 
polymerase chain reaction (PCR) was used to amplify polymorphic 
microsatellite markers capable of distinguishing maternal and paternal 
copies of chrom osom e 18. Allelic loss was observed as the absolute loss of 
the PCR product corresponding to the lost chromosomal arm.
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6.2. Frequency of Allelic Imbalance on Chromosome 18 in 
Ductal Carcinoma in-situ.
Eleven patients with isolated DCIS were analysed with three polymorphic 
markers for chromosome 18 and the results of the analysis are presented in 
(Table 1).
Chromosome Region No. of cases with LOH
18pll.32 8 / 11  (72%)
18pll.22 6 /11 (55%)
18q23 9/ 11  (82%)
Table 1. Frequency of Allelic Imbalances in DCIS for Chromosome 18 
markers, D18S59 (18pll.32), D18S71 (18pll.22)
D18S70 (18q23).
The polymorphic markers for the region 18pl 1.32 showed allelic imbalance in 
8 / 1 1  patients, (72%); while the marker for 18p 11.22 showed allelic 
imbalance in 6 / 11 patients, (55%); the highest frequency of allelic imbalance 
was demonstrated for the region 18q23 which showed allelic imbalance in 9 / 
11 patients, (82%). This data complements the interphase cytogenetic findings 
for each section which demonstrated a loss of chromosome 18-centromeric 
sequences.
6.3. Intratumour Heterogeneity for Allelic Imbalances.
Each section of DCIS had up to nine separate ducts containing DCIS 
microdissected from toluidine blue stained paraffin sections, the DNA 
extracted and the subsequent PCR products separated on acrylamide gels to 
detect allelic imbalances,( Figure 3).
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Figure 3. Example of PCR products from a microdissected 
section separated on an acrylamide gel.
Of the 11 patients analysed 10 patients had tumour foci informative for all 
three polymorphic markers and it was only those 10 sections that were 
included in the analysis, (Table 2).
Of the 62 individual ducts microdissected from 11 patients, 31 of these ducts 
from 10 patients were informative for all three markers, (Table 2). D18S59 
showed allelic imbalance in 8 / 10 patients and in 14 / 31 ducts (LOH 
frequency of 45%) while D18S71 showed allelic imbalance in 6 / 10 patients 
and 12 / 31  ducts (LOH frequency of 39%). The highest frequency of allelic 
imbalance for an chromosomal region was for the marker D18S70, with 9 / 1 0  
patients showing allelic imbalances and 2 0 / 3 1  ducts (LOH frequency of 
65%). This estimation of the frequency of allelic imbalance may be a more 
accurate reflection of the rate of LOH for DCIS as it takes into account the 
number of DCIS foci examined in each section, whereas the percentage of 
patients with LOH, does not, (Table 1).
The striking feature of (Table 2), is the extensive heterogeneity of allelic 
imbalances within sections of DCIS. The data from patient 3 illustrates this 
phenomenon, (Figure 4 & Figure 5). Patient 3 had three separate foci of DCIS 
microdissected together with a normal lobule. The normal lobule retained both 
alleles for all three markers. Duct 1 retained both alleles for the p-arm markers 
but lost the upper allele for the q-arm marker. Duct 2 again retained both the 
alleles of the p-arm markers however lost the opposite lower allele for the q- 
arm marker. Duct 3 lost the upper allele for D18S59 but retained both alleles 
for the other markers.
This genetic disparity between foci of DCIS was present in all the sections 
analysed and is schematically represented in (Figure 5).
In some sections, such as section 3, (Figure 4), genetic alterations on 
chromosome 18 were similar in different foci of DCIS and similar to the 
invasive component of the section. However, in other sections, such as section 
6, the invasive component demonstrated different alterations.
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Patient 1 2 3 4 5 6 7 8 9  10 11 Total
No. o f ducts 
informative 
for all 3 markers
6 3 3 4 2 2 2 0 3 4 2 31
Locus | Ducts demonstrating allelic imbalance | LOH %
D18S59
D18S71
D18S70
1 1 1 0 0 2 2 0 3 3 1  
1 0 0 3 0 2 0 0 2  3 1 
4 1 2 4 0 1 1 0 3 2 2
14/31 (45%) 
12/31 (39%) 
20/31 (65%)
Table 2. Results of PCR amplification of 3 polymorphic markers for 
multiple foci of DCIS. ( eg: Patient one had 6 DCIS foci 
informative for all three markers. 1 / 6  ducts showed allelic 
imbalance for the marker D18S59 and D18S71 while 4 / 6  ducts 
showed allelic imbalance for the marker D18S70. The 
remaining ducts showed retention of both alleles.)
Ducts 1 2 3 4 -ve
1 1 i  1 1
D 1 8 S 5 9
B
i t  i
a l l e l e  1
a l l e l e  2
n d d d
Ducts 1 2 3 4 -ve
J U H
D 1 8 S 7 0
1 * :
-  a l l e l e  1  
a l l e l e  2
n d d d
Figure 4. Microsatellite analysis of section 3. 
( n - normal; d - DCIS )
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A feature of the heterogeneity between ducts was the frequent observation that 
spacially related ducts lost opposite alleles for the same polymorphic marker, 
(Figure 5; examples are boxed). This phenomenon has been reported by other 
authors but at a low frequency (Stratton et al. 1995).
6.4. Discussion.
Interphase cytogenetics previously demonstrated that whole chromosome 18 
loss was a feature of DCIS. This has now been complemented by 
microsatellite analysis which has shown regional chromosome 18 alterations 
in DCIS. The frequency of these allelic imbalances were far higher than 
previously reported regional chromosome 18 changes. The factors which 
contributed to the high frequencies of allelic imbalances observed are firstly, 
the precise microdissection of ducts with DCIS which reduces to a minimum 
the potential for normal cellular contamination which would mask allelic loss. 
Secondly, examination of multiple foci of DCIS within each section has 
revealed that allelic imbalances are not uniformly present in all portions of a 
tumour and would be missed or underestimated if only one area of DCIS had 
been analysed.
The markers on the p-arm of chromosome 18 (D18S59 &D18S71) 
demonstrated a frequency of allelic imbalance of 45% and 39% respectively. 
The p-arm of chromosome 18 has not been subjected to a great deal of 
analysis before in DCIS or invasive breast cancer. However, despite this, the 
frequency of alterations are high suggesting that the p-arm of chromosome 18 
should be revisited in breast cancer and other tumours as a possible region of 
importance.
In contrast to the p-arm of chromosome 18, the q-arm has been the'subject of 
intensive research in many tumours and indeed chromosome 18q has been 
implicated to contain tumour suppresser genes. One such gene is DCC, which 
has been isolated and cloned from 18q21 and has been found to be deleted in a 
number of tumours but most commonly in colonic carcinoma (Devilee et al.
60
1991). LOH / allelic imbalance at this locus has also been observed in 
invasive breast cancer ranging from 16% to 43% (Devilee et al. 1991). Hence 
DCC is thought to play an important role in the evolution of breast cancer.
18q21 also harbours a tumour suppresser gene, DPC4 / Smadl, which has 
been implicated in a number of tumours including pancreatic, ovarian, lung 
and head & neck (Hahn et al. 1996). Recent analysis has also shown that there 
is a high frequency of allelic imbalance in this region in invasive breast cancer 
also, outwith the locus of DCC (Schenk et al. 1996).
However, perhaps the most promising area on 18q that may harbour a 
suppresser gene is 18q23 (Huang et al. 1995). Our data demonstrates a 
frequency of allelic imbalance on 18q23, which includes this locus, of 63% in 
DCIS which is in concordance with analysis of this locus in invasive disease, 
with allelic imbalance in this area being detected in up to 43% of patients with 
breast cancer (Devilee et al. 1991). In addition, the rate <?f allelic imbalance of 
18q23 in ovarian cancer is reported to be 60%, greater than that of the DCC 
gene, hence this suggests that 18q23 may contain another tumour suppresser 
gene common to both breast and ovarian cancer (Kerr J.et al et al. 1992). The 
high frequency of allelic imbalance in DCIS also suggests that this region may 
be involved in an early stage of progression and that the alterations observed 
in this region are not just an epiphenomenon as a result of the genetic 
instability induced by the malignant phenotype.
A striking feature of the pattern of allelic imbalance in DCIS was the marked 
genetic heterogeneity between ducts, (Figure 5). The analysis of the multiple 
foci of DCIS raises several issues. Firstly, the identification of similar 
alterations to chromosome 18 in DCIS and invasive tumour from the same 
section, (Figure 3; section 9) provides further evidence for the clonal evolution 
of DCIS to invasive cancer. Secondly, the demonstration of different 
alterations to chromosome 18 in different foci of DCIS provides evidence of 
subclonal evolution within a section of DCIS.
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This hypothesis of subclonal evolution is demonstrated in (Figure 6), which is 
a representation of the genetic alterations to the three individual ducts from 
section 3. A number of key chromosomal alterations must be attained during 
the development of a tumour to reach the malignant phenotype. The allelic 
imbalance at 18q23 present in ducts 1 and 2, although affecting different 
alleles may be important in the evolution of that subclone. This could be via a 
gene dosage effect which confers a growth advantage on that clone thus 
selecting for that clone with the 18q23 alteration to evolve and diversify 
further and possibly gain further critical chromosomal alterations which may 
breach the biological barrier of invasion. Hence, the alteration to 18q23 will be 
present at a high frequency in a number of subsequent subclones and may well 
be associated with further alterations to chromosome 18. Although present at a 
lower frequency, the alteration to the p-arm in duct 3 may also provide a 
growth advantage which allows the progression along a different pathway of 
subclone evolution.
Indications from the interphase cytogenetic analysis of PDWA suggest that 
chromosome 18 alterations occur early in the evolution of breast cancer 
progression, hence alterations to key genes on chromosome 18 could prove to 
be the target of future preventative therapy for breast cancer. The process of 
subclone evolution is clearly complex even for one chromosome, however, the 
technique of microdissection and the analysis of multiple foci of DCIS may 
well result in the detection of genetic alterations critical for a subclone to 
develop the potential to invade.
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Figure 6. Subclonal evolution of DCIS
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7. General Discussion
In recent years we have seen improvements in the multidisciplinary treatment 
of breast cancer which has led to modest improvements in disease free interval 
and survival for stage I and stage II invasive breast cancer. However, the 
incidence of breast cancer continues to increase and will continue to do so 
unless the biological nature of the disease is understood and novel therapeutic 
strategies can be developed both to treat and prevent breast cancer.
In an attempt to alter the natural history of breast cancer by diagnosing it as 
early as possible, before the tumour has developed a potential to metastasise, 
mammographic screening was introduced. This has led to an explosion in the 
diagnosis of all forms of pre-invasive breast lesions. Advances in molecular 
biology and recombinant DNA technology have provided the tools to analyse 
both breast cancer and its potential precursors in an attempt to determine the 
critical genetic alterations that lead to the invasive phenotype.
As you might expect the majority of genetic investigation has been conducted 
on invasive disease and more recently ductal carcinoma in-situ, which has 
provided strong evidence that DCIS is a non-obligate precursor of breast 
cancer. However, little is known about the genetics of early breast cancer 
progression.
The aim of this study was to reconstruct the molecular evolution of breast 
cancer progression with particular emphasis on the critical pre-invasive steps. 
Interphase cytogenetics allowed the identification of chromosomal alterations 
common to a subpopulation of PDWA and DCIS, providing for the first time 
genetic evidence that DCIS and thus invasive breast cancer are genetically 
similar to a group of benign lesions that are known to convey a higher risk of 
breast cancer to the individual. This provides important evidence to
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substantiate the hypothesis that a normal breast epithelium can evolve through 
a number of sequential genetic alterations to invasive carcinoma, (Figure 1). 
The presence of similar genetic alterations in PDWA and DCIS suggests that 
crucial initiating or transforming changes occur early in breast cancer 
progression. The pattern of genetic alterations identified in PDWA and DCIS 
also sets an agenda for the future investigation of pre-invasive breast disease. 
For instance the huge increase in frequency of chromosome 3 and 17 
alterations between PDWA and DCIS suggests that those chromosomes 
harbour genes critical in the progression of a benign precursor to one with a 
high potential to transform into invasive breast cancer.
One such gene is ERBB2 (Chi7) which is amplified in a proportion of DCIS 
and invasive cancers but not in PDWA. Hence, the amplification of this 
oncogene may be associated with the progression of a subpopulation of 
PDWA to DCIS. However, only approximately 30% of DCIS show 
amplification of this oncogene. The subsequent analysis of initial and 
recurrent DCIS samples revealed that ERBB2 amplification was not crucial to 
the development of invasive recurrences following initial wide excision of 
pure DCIS. These findings imply that there are a number of pathways of 
sequential gene alterations that can lead to invasive cancer one of which 
involves chromosome 17 and the amplification of ERBB2. It therefore appears 
that alterations to chromosome 17, including ERBB2, are not involved in the 
final common pathway to invasion.
The demonstration that the progression of PDWA to DCIS was also associated 
with an increased frequency of chromosome 3 alterations was of particular 
interest because our group have just mapped the human telomerase gene, 
(hTR), to chromosome 3q26.6. and have demonstrated amplification of this 
gene in a number of solid tumours.
The reactivation of telomerase activity, which maintains telomere length in 
dividing cells, conveys immortality to those cells and may well be a 
fundamental feature of cancer progression. It therefore seems reasonable to
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hypothesise that the chromosome 3 alterations identified in PDWA and DCIS 
could include amplification of the hTR gene locus resulting in the reactivation 
of telomerase and the establishment of a small subpopulation of PDWA which 
evolves to DCIS as a result.
Future analysis of breast cancer and pre-invasive breast disease will determine 
the significance of these observations, however the discovery of the 
telomerase gene on a chromosome known to be altered in breast cancer and 
pre-invasive lesions provides the opportunity to develop new therapies for 
breast cancer. For example, an ‘anti-telomerase’ agent. Indeed, if the function 
and interactions of the promoter region of this gene can be elucidated, the 
opportunity exists to develop novel therapies to prevent the amplification of 
the gene and therefore potentially prevent breast cancer progression.
The interphase cytogenetic analysis of PDWA and DCIS indicated that 
chromosome 18 alterations occurred at a high frequency in both pre-invasive 
lesions suggesting that genetic alterations to chromosome 18 are an early event 
in the sequential genetic progression to invasive breast cancer or that one 
particular pathway to invasion involves alterations to chromosome 18 genes. 
The study subsequently demonstrated regional alterations to chromosome 18 
in DCIS, pinpointing 18q23 as a region likely to harbour a new tumour 
suppresser gene or genes.
Those regional changes on chromosome 18 were subject to extensive 
intratumour variation or heterogeneity, implying that a section of DCIS is 
composed of multiple subclones of DCIS, each with differing genetic 
alterations seeking the correct combination of genetic alterations that will 
allow that particular clone to breach the biological barrier of invasion. Those 
divergent clones of DCIS are thought to have evolved from PDWA, therefore 
in theory PDWA should also be composed of subclones, less genetically 
mature than those of DCIS. However, FISH was not sensitive enough to detect 
intratumour variation in this study.
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The objective of this study was to provide scientific evidence for the 
hypothesis that breast cancer can evolve from benign precursors by identifying 
genetic alterations common to those benign lesions and breast cancer. The 
results of the study have accomplished this and indeed identified certain 
chromosomes and chromosomal regions that may harbour genes critical to 
early breast cancer progression. The results of this study together with other 
groups analyses of DCIS and invasive breast cancer provide compelling 
genetic evidence that the invasive phenotype is a result of one or more 
subclones of cells derived from a normal breast epithelium which has evolved 
and diverged from related clones of cells on its path toward invasion, (Figure 
1). Those multiple clones are arbitrarily called PDWA, ADH and DCIS based 
on their light microscopic appearances, however they all represent the same 
biologically evolving clones of cells at different stages in their maturity.
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